var title_f0_37_592="Diaphragm";
var content_f0_37_592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54756%7EOBGYN%2F69595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54756%7EOBGYN%2F69595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragm fitting kit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_592=[""].join("\n");
var outline_f0_37_592=null;
var title_f0_37_593="Chondro histology";
var content_f0_37_593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Histology of grade 1, 2, and 3 chondrosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    While cellularity is low in grade 1 chondrosarcoma (A) with chondroid matrix and absent mitoses, in grade 2 chondrosarcoma (B) mitoses are found (inset). In grade 3 chondrosarcoma (C), a high cellularity with muco-myxoid matrix changes is seen with cytonuclear atypia (hematoxylin and eosin staining, &sim;500X).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright &copy;2008 AlphaMed Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.TheOncologist.com\">",
"      file://www.TheOncologist.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_593=[""].join("\n");
var outline_f0_37_593=null;
var title_f0_37_594="Echocardiogram D-TGA";
var content_f0_37_594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram of D-transposition of the great arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Echocardiogram of D-transposition of the great arteries. Subcostal short axis view demonstrates the anteriorly positioned right ventricle (RV) giving rise to the aorta (Ao). The pulmonary artery (PA) is posteriorly related to the aorta and arises from the left ventricle. The aorta is identified as the vessel that gives rise to the head and neck vessels as well as the coronary arteries, while the pulmonary artery branches into the right and left pulmonary arteries. Mixing of blood between the two parallel circuits occurs through the patent ductus arteriosus (PDA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_594=[""].join("\n");
var outline_f0_37_594=null;
var title_f0_37_595="Patient information: Secondhand smoke: Risks to children (The Basics)";
var content_f0_37_595=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/28/24002\">",
"         Patient information: Acute bronchitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/58/17315\">",
"         Patient information: Asthma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/7/13427\">",
"         Patient information: Cough in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/38/44642\">",
"         Patient information: Ear infections (otitis media) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/17/14611\">",
"         Patient information: Pneumonia in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/38/38497\">",
"         Patient information: Sudden infant death syndrome (SIDS) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/0/37892\">",
"         Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/16/15619\">",
"         Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/40/7811\">",
"         Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Secondhand smoke: Risks to children (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H287369052\">",
"      <span class=\"h1\">",
"       What is secondhand smoke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Secondhand smoke is the term doctors use for the smoke that people (who do not smoke) breathe in from other people&rsquo;s smoking. Another term for secondhand smoke is &ldquo;environmental tobacco smoke.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369067\">",
"      <span class=\"h1\">",
"       Does secondhand smoke cause health problems in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Studies have shown that secondhand smoke from people smoking in the home can cause health problems in children. These problems are worse if both parents smoke.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369082\">",
"      <span class=\"h1\">",
"       What health problems can secondhand smoke cause in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Secondhand smoke increases the chance of children having the following health problems:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breathing symptoms, such as coughing, coughing up mucus, or wheezing (noisy breathing)",
"       </li>",
"       <li>",
"        Lung infections, such as bronchitis and pneumonia &ndash; These infections can be especially serious in babies and young children.",
"       </li>",
"       <li>",
"        Asthma &ndash; Asthma is a lung condition that makes it hard to breathe. It doesn&rsquo;t cause symptoms all the time. But when symptoms flare up, children wheeze, cough, or get a tight feeling in their chest.",
"       </li>",
"       <li>",
"        The lungs not growing normally during childhood",
"       </li>",
"       <li>",
"        Ear infections",
"       </li>",
"       <li>",
"        Hearing loss (later in childhood)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Later on as adults, children who grew up with secondhand smoke are more likely to get:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Asthma",
"       </li>",
"       <li>",
"        Lung cancer",
"       </li>",
"       <li>",
"        Other types of cancers",
"       </li>",
"       <li>",
"        Heart disease",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Also, children who grow up with parents who smoke are more likely to take up smoking themselves.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369097\">",
"      <span class=\"h1\">",
"       What if my child already has asthma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child already has asthma, secondhand smoke can make his or her symptoms worse or severe. Also, secondhand smoke causes children with asthma to need their asthma medicines or go to the hospital more often.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369112\">",
"      <span class=\"h1\">",
"       Can secondhand smoke affect an unborn baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If a woman (who doesn&rsquo;t smoke) lives in a home with secondhand smoke, her baby has a higher chance of weighing less than normal at birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369127\">",
"      <span class=\"h1\">",
"       What problems can happen if a woman smokes during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who smoke during pregnancy have a higher chance of having a miscarriage, which is when a pregnancy ends on its own.",
"     </p>",
"     <p>",
"      When a woman smokes during pregnancy, her baby has a higher chance of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Being born too early",
"       </li>",
"       <li>",
"        Not growing as much as normal in the uterus (womb)",
"       </li>",
"       <li>",
"        Being born with a birth defect",
"       </li>",
"       <li>",
"        Dying from sudden infant death syndrome (called &ldquo;SIDS&rdquo;) later on &ndash; SIDS is when a baby dies suddenly during sleep for no known reason.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369142\">",
"      <span class=\"h1\">",
"       Is it enough to just make a smoke-free room in my home?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. If you want to help your child&rsquo;s health, you need to make your whole home smoke-free. You also need to make your car smoke-free. It will not help enough to make a smoke-free room, smoke at home only when your child is not there, or use an air cleaner.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369157\">",
"      <span class=\"h1\">",
"       What should I do if I want to quit smoking?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to quit smoking, think of the letters in the word &ldquo;START.&rdquo; They can help you remember the steps to take:",
"     </p>",
"     <p>",
"      S = Set a quit date.",
"     </p>",
"     <p>",
"      T = Tell family, friends, and the people around you that you plan to quit.",
"     </p>",
"     <p>",
"      A = Anticipate or plan ahead for the tough times you&rsquo;ll face while quitting.",
"     </p>",
"     <p>",
"      R = Remove cigarettes and other tobacco products from your home, car, and work.",
"     </p>",
"     <p>",
"      T = Talk to your doctor or nurse about getting help to quit.",
"     </p>",
"     <p>",
"      Your doctor or nurse can help you in different ways. He or she can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Put you in touch with a counselor &ndash; A counselor can help you figure out what triggers your smoking and what you can do instead.",
"       </li>",
"       <li>",
"        Prescribe medicines to help you quit smoking &ndash; Some medicines reduce your craving for cigarettes. Others reduce unpleasant symptoms (called &ldquo;withdrawal symptoms&rdquo;) that happen when you stop smoking.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can also get help from a free phone line (1-800-QUIT-NOW) or the Web site",
"      <a class=\"external\" href=\"file://www.smokefree.gov/\">",
"       www.smokefree.gov",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H287369172\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       Patient information: Asthma in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"       Patient information: Cough in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=see_link\">",
"       Patient information: Pneumonia in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/28/24002?source=see_link\">",
"       Patient information: Acute bronchitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=see_link\">",
"       Patient information: Ear infections (otitis media) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/38/38497?source=see_link\">",
"       Patient information: Sudden infant death syndrome (SIDS) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"       Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"       Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/40/7811?source=see_link\">",
"       Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/37/595?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86148 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_595=[""].join("\n");
var outline_f0_37_595=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369052\">",
"      What is secondhand smoke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369067\">",
"      Does secondhand smoke cause health problems in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369082\">",
"      What health problems can secondhand smoke cause in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369097\">",
"      What if my child already has asthma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369112\">",
"      Can secondhand smoke affect an unborn baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369127\">",
"      What problems can happen if a woman smokes during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369142\">",
"      Is it enough to just make a smoke-free room in my home?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369157\">",
"      What should I do if I want to quit smoking?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H287369172\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/28/24002?source=related_link\">",
"      Patient information: Acute bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=related_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=related_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/40/7811?source=related_link\">",
"      Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/38/38497?source=related_link\">",
"      Patient information: Sudden infant death syndrome (SIDS) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_37_596="Edrophonium: Pediatric drug information";
var content_f0_37_596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Edrophonium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"    see \"Edrophonium: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enlon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F164243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Enlon&reg;;",
"     </li>",
"     <li>",
"      Tensilon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Neuromuscular Blocking Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diagnostic Agent, Myasthenia Gravis",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"      see \"Edrophonium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usually administered I.V., however, if not possible, I.M. or SubQ may be used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Infants: Diagnosis of myasthenia gravis: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., SubQ: 0.5-1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 0.1 mg, followed by 0.4 mg (if no response); total dose = 0.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diagnosis of myasthenia gravis: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ: &le;34 kg: 2 mg; &gt;34 kg: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 0.04 mg/kg given over 1 minute followed by 0.16 mg/kg given within 45 seconds (if no response) (maximum dose: 10 mg total)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternative (manufacturer's recommendations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &le;34 kg: 1 mg; if no response after 45 seconds, it may be repeated in 1 mg increments every 30-45 seconds to a total of 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;34 kg: 2 mg; if no response after 45 seconds, it may be repeated in 1 mg increments every 30-45 seconds to a total of 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Titration of oral anticholinesterase therapy: I.V.: 0.04 mg/kg once given 1 hour after oral intake of the drug being used in treatment; if strength improves, an increase in neostigmine or pyridostigmine dose is indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diagnosis of myasthenia gravis: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ: Initial: 10 mg; if no cholinergic reaction occurs, administer 2 mg 30 minutes later to rule out false-negative reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 2 mg test dose administered over 15-30 seconds; 8 mg given 45 seconds later (if no response is seen); test dose may be repeated after 30 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Titration of oral anticholinesterase therapy: I.V.: 1-2 mg given 1 hour after oral dose of anticholinesterase; if strength improves, an increase in neostigmine or pyridostigmine dose is indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Differentiation of cholinergic from myasthenic crisis: I.V.: 1 mg, may repeat after 1 minute (",
"     <b>",
"      Note:",
"     </b>",
"     Intubation and controlled ventilation may be required if patient has cholinergic crises.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reversal of nondepolarizing neuromuscular blocking agents (neostigmine with atropine usually preferred): I.V.: 10 mg over 30-45 seconds, may repeat every 5-10 minutes up to 40 mg total dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Termination of paroxysmal atrial tachycardia: I.V.: 5-10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Dose may need to be reduced in patients with chronic renal failure",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enlon&reg;: 10 mg/mL (15 mL) [contains natural rubber/natural latex in packaging, sodium sulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Edrophonium is administered by direct I.V. or I.M. injection",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F164267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnosis of myasthenia gravis; differentiation of cholinergic crises from myasthenia crises; reversal of nondepolarizing neuromuscular blockers; treatment of paroxysmal atrial tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F164266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (especially bradycardia), AV block, carbon monoxide decreased, cardiac arrest, ECG changes (nonspecific), flushing, hypotension, nodal rhythm, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Convulsions, dizziness, drowsiness, dysarthria, dysphonia, headache, loss of consciousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin rash, thrombophlebitis (I.V.), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dysphagia, flatulence, hyperperistalsis, nausea, salivation, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary urgency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgias, fasciculations, muscle cramps, spasms, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, small pupils",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchiolar constriction, bronchospasm, dyspnea, bronchial secretions increased, laryngospasm, respiratory arrest, respiratory depression, respiratory muscle paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, diaphoresis increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to edrophonium or any component; GI or GU mechanical obstruction",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in asthmatic patients, patients with cardiac dysrhythmias, and those receiving a cardiac glycoside",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Overdosage can cause cholinergic crisis which may be fatal; I.V. atropine should be readily available for treatment of cholinergic reactions; injection contains sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pre- and postinjection strength (cranial musculature is most useful); heart rate, respiratory rate, blood pressure, changes in fasciculations",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits destruction of acetylcholine by acetylcholinesterase. This facilitates transmission of impulses across myoneural junction and results in increased cholinergic responses such as miosis, increased tonus of intestinal and skeletal muscles, bronchial and ureteral constriction, bradycardia, and increased salivary and sweat gland secretions",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 2-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 5-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5-10 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 1.18 &plusmn; 0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.22 &plusmn; 0.74 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.9 &plusmn; 0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 73 &plusmn; 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 99 &plusmn; 31 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 126 &plusmn; 59 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 17.8 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 14.2 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 8.3 &plusmn; 2.9 mL/kg/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13266 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-B1BE4F5CD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_596=[""].join("\n");
var outline_f0_37_596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164242\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164243\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058297\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058292\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164225\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164211\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058301\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164267\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058300\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164266\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058305\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058291\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058290\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299253\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164219\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058296\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058289\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058303\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058304\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13266\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13266|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=related_link\">",
"      Edrophonium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_37_597="Inflammatory bowel disease CT";
var content_f0_37_597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary parenchymal involvement in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT scan shows multiple necrobiotic nodules (biopsy-proven) in a patient with Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_597=[""].join("\n");
var outline_f0_37_597=null;
var title_f0_37_598="Primary TB in an infant PA";
var content_f0_37_598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary tuberculosis in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large left sided pleural effusion produces complete opacification of the left hemithorax with cardiomediastinal shift to the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_598=[""].join("\n");
var outline_f0_37_598=null;
var title_f0_37_599="Structure of the tooth";
var content_f0_37_599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structure of the tooth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Leeson CR, Leeson TS, Paparo AA. Textbook of Histology, 5th ed, WB Saunders, Philadelphia, 1985, p.318.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_599=[""].join("\n");
var outline_f0_37_599=null;
var title_f0_37_600="Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4";
var content_f0_37_600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/600/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/600/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/600/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/600/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/600/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/37/600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12153729\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. The acute process is self-limited, rarely causes hepatic failure, and usually leads to chronic infection. Chronic HCV infection often follows a progressive course over many years and can ultimately result in cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of treatment is to eradicate HCV RNA, which is predicted by the achievement of a sustained virologic response (SVR) as defined by the absence of HCV RNA by polymerase chain reaction six months after stopping treatment. An SVR is associated with a 99 percent chance of being HCV RNA negative during long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/1\">",
"     1",
"    </a>",
"    ]. Achievement of an SVR has also been associated with improved clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=see_link&amp;anchor=H9#H9\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\", section on 'Long-term efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link&amp;anchor=H9643992#H9643992\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'Goal of antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the treatment of patients with chronic HCV genotypes 2, 3, and 4. Treatment of patients with genotype 1, data regarding the efficacy of various treatment regimens, experimental agents for the treatment of HCV, the treatment of acute HCV, the selection of patients for treatment, the management of treatment-induced side effects, and factors that predict a response to treatment are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"       \"Overview of the management of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"       \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"       \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link\">",
"       \"Investigational therapies for hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"       \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link\">",
"       \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19315213\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment guidelines for chronic hepatitis C virus (HCV) infection were published in 2009 by the American Association for the Study of Liver Diseases (AASLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/2\">",
"     2",
"    </a>",
"    ] and can be accessed at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    . The discussion that follows is consistent with the AASLD guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488642015\">",
"    <span class=\"h1\">",
"     FACTORS ASSOCIATED WITH A RESPONSE TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several host and viral characteristics have been associated with a response to antiviral therapy and are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488642863\">",
"    <span class=\"h1\">",
"     SELECTION OF PATIENTS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;How to determine which patients are candidates for treatment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488641848\">",
"    <span class=\"h1\">",
"     MONITORING VIRAL LOAD DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once therapy has been started, the likelihood that a patient will fail to achieve a sustained virologic response (SVR) can be predicted by the virologic response at 12 weeks of therapy, and probably even earlier. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H32984769#H32984769\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Changes in viral load during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rapid virologic response is the strongest on-treatment predictor of achieving an SVR. Some but not all data suggest that shorter courses of therapy (eg, 24 weeks) may not adversely affect patients who achieve a rapid virologic response (negative HCV RNA after four weeks of treatment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link&amp;anchor=H15546553#H15546553\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\", section on 'Shortening therapy for patients who achieve an RVR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An early virologic response (EVR) is defined as at least a 2 log",
"    <sub>",
"     10",
"    </sub>",
"    reduction in HCV RNA or HCV RNA negativity by week 12. A patient with a \"complete EVR\" has attained complete viral suppression by week 12; a patient with a \"partial EVR\" has achieved greater than a 2 log",
"    <sub>",
"     10",
"    </sub>",
"    decline in viremia but continues to have detectable HCV RNA. An SVR is unlikely in patients who lack an EVR, and it is generally recommended that treatment be stopped in patients who fail to achieve an EVR. Patients who are \"partial responders\" have lower overall SVR rates compared with complete responders (ie, no detectable viremia at 12 weeks). Studies are ongoing to determine if there are patients, such as patients who have a slow decline in HCV RNA, who would benefit from extended courses of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link&amp;anchor=H15546859#H15546859\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\", section on 'Lengthening therapy for those who fail to achieve a complete EVR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest that patients have their viral loads checked at baseline and at weeks 4, 12, and 24 of therapy to assess for a treatment response and to make decisions about continuing treatment or possibly altering the duration of treatment. Patients with an end of treatment response (negative HCV RNA at the completion of treatment) should also have a viral load checked 24 weeks after therapy is completed to assess for an SVR. An SVR is associated with a 99 percent chance of being HCV RNA negative during long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19310924\">",
"    <span class=\"h1\">",
"     CHOICE OF PEGINTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peginterferon alfa-2a (Pegasys, Roche Pharmaceuticals) and peginterferon alfa-2b (Peg-Intron, Schering-Plough Corporation) differ in their pharmacokinetics. Studies comparing the two peginterferons in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    have had variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. While the largest randomized trial (IDEAL) showed that peginterferon alfa-2a and peginterferon alfa-2b appeared to have comparable efficacies in the treatment of chronic hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/4\">",
"     4",
"    </a>",
"    ], meta-analyses suggest a slight advantage for peginterferon alfa-2a [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One meta-analysis compared sustained virologic response (SVR) rates and adverse event rates between patients treated with peginterferon alfa-2a and alfa-2b [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/10\">",
"     10",
"    </a>",
"    ]. The analysis included only randomized controlled trials. Eight trials with 4335 patients were included in the analysis of SVR rates. The analysis found that peginterferon alfa-2a was superior to peginterferon alfa-2b (SVR rates of 47 versus 41 percent; relative risk [RR] 1.11, 95% confidence interval [CI] 1.04-1.19).",
"   </p>",
"   <p>",
"    When patients with genotypes 1 and 4 were examined, the results continued to favor peginterferon alfa-2a (RR 1.21, 95% CI 1.03-1.24). Similar results were noted for patients with genotypes 2 and 3 (RR 1.11, 95% CI 1.02-1.22). There was no difference between the treatments with regard to adverse events, though the number of patients included in the meta-analysis was too small to draw definitive conclusions. We suggest treatment with peginterferon alfa-2a in patients with chronic HCV genotype 2, 3, or 4 rather than treatment with peginterferon alfa-2b.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488644295\">",
"    <span class=\"h1\">",
"     DOSES OF PEGINTERFERON AND RIBAVIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two peginterferon preparations used in the treatment of HCV (peginterferon alfa-2a and peginterferon alfa-2b). The doses of peginterferon differ for the two preparations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For peginterferon alfa-2a, the dose is 180 micrograms subcutaneously per week",
"     </li>",
"     <li>",
"      For peginterferon alfa-2b, the dose is 1.5",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      subcutaneously per week",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending on the genotype being treated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dosing may or may not be weight-based. Ribavirin is given in divided daily doses (typically twice per day). For genotypes 2 and 3, ribavirin dosing is not weight-based. Patients instead receive a standard dose of 800 mg (typically 400 mg twice daily).",
"   </p>",
"   <p>",
"    For genotype 4,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is weight-based:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving peginterferon alfa-2a, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dose is 1000 mg for patients who weigh 75 kg or less, or 1200 mg for those who weigh more than 75 kg.",
"     </li>",
"     <li>",
"      For patients receiving peginterferon alfa-2b, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      dose is 800 mg for patients weighing &lt;65 kg, 1000 mg for 65 to 85 kg, 1200 mg for &gt;85 to 105 kg, and 1400 mg for &gt;105 kg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488642654\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488640991\">",
"    <span class=\"h2\">",
"     Treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with genotype 2, 3, or 4 should receive dual therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Protease inhibitors are",
"    <strong>",
"     not",
"    </strong>",
"    used in the treatment of patients with genotype 2, 3, or 4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488642640\">",
"    <span class=\"h3\">",
"     Genotype 2 or 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with genotype 2 or 3 should receive treatment with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Ribavirin is not weight-based for the treatment of genotypes 2 or 3. All patients receive 800 mg in daily divided doses (typically 400 mg twice daily). Treatment with peginterferon plus ribavirin should be administered for 24 weeks in patients with genotype 2 or 3. These patients generally have a better response to peginterferon and ribavirin than those with genotype 1 or 4. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H16092652#H16092652\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Viral factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H488642647\">",
"    <span class=\"h3\">",
"     Genotype 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with genotype 4 should received treatment with peginterferon and weight-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Treatment with peginterferon plus weight-based ribavirin should be planned for 48 weeks, but the actual duration of therapy will be determined in part by the viral response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=see_link\">",
"     \"Response-guided therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment should be discontinued in patients who do not achieve at least a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      reduction in HCV RNA at week 12 (ie, early virologic response). (See",
"      <a class=\"local\" href=\"#H488641848\">",
"       'Monitoring viral load during therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have at least a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      reduction in HCV RNA but still have detectable HCV RNA at week 12 should be retested at week 24. Treatment should be discontinued if HCV RNA continues to be positive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154514\">",
"    <span class=\"h2\">",
"     Relapsers and nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations from the National Institutes of Health and the American Association for the Study of Liver Diseases suggest that retreatment of patients who did not achieve a sustained virologic response (SVR) with prior interferon-based therapy should be based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The previous type of response",
"     </li>",
"     <li>",
"      The previous therapy and the difference in the potency of the new therapy",
"     </li>",
"     <li>",
"      The severity of the underlying liver disease",
"     </li>",
"     <li>",
"      Viral genotype and other predictive factors of response",
"     </li>",
"     <li>",
"      Tolerance and compliance with previous therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link&amp;anchor=H12156576#H12156576\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\", section on 'Retreatment of prior nonresponders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154102\">",
"    <span class=\"h3\">",
"     Prior treatment with standard interferon monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who relapse after an initial response to interferon monotherapy, we recommend combination therapy with peginterferon plus weight-based",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Patients who are nonresponders to interferon monotherapy are less likely to respond to combination therapy compared with those who relapsed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/12\">",
"     12",
"    </a>",
"    ]. In prior nonresponders, we suggest a trial of combination therapy with peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in patients who tolerated interferon monotherapy and have moderate to advanced histologic features on liver biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154109\">",
"    <span class=\"h3\">",
"     Prior treatment with standard interferon and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for nonresponders or relapsers following combination therapy with standard interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    include observation, enrollment in a clinical trial, or a course of peginterferon plus ribavirin.",
"   </p>",
"   <p>",
"    Data suggest that the response to peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in these patients is in the range of 10 to 20 percent overall, though the studies also included patients with genotype 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/13\">",
"     13",
"    </a>",
"    ]. Higher response rates are seen in patients infected with genotype 2 or 3, in relapsers, and in patients who do not have cirrhosis. If treatment is to be given, we suggest it be administered for 24 weeks for patients with genotype 2 or 3 or for 48 weeks for patients with genotype 4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154116\">",
"    <span class=\"h3\">",
"     Prior treatment with peginterferon and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients who are nonresponders to peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is unsettled. For those who failed treatment with a full course of peginterferon alfa-2a or alfa-2b plus ribavirin, we generally do not suggest retreatment with peginterferon and ribavirin.",
"   </p>",
"   <p>",
"    Retreatment can be considered in selected patients who had a partial response to previous therapy or had an interrupted or inadequate course of therapy. The results of the patient's liver biopsy help guide the decision to retreat. If the biopsy was performed within five years and there was minimal or no fibrosis, we do not retreat. If the biopsy showed moderate or severe fibrosis and the patient tolerated therapy well, we will offer the patient retreatment. For patients who did not tolerate the treatment, the decision to offer retreatment is less clear and will depend in large part on the patient's preferences. For patients who have not had a liver biopsy within the last five years, we repeat the liver biopsy prior to making retreatment decisions.",
"   </p>",
"   <p>",
"    There is some evidence supporting the use of a different form of peginterferon for patients who are being retreated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link&amp;anchor=H12156576#H12156576\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\", section on 'Retreatment of prior nonresponders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12158458\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY IN NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies had suggested that interferon-based treatments may be associated with clinical improvement, even in patients who do not achieve an SVR. However, final results of the HALT-C trial (evaluating low-dose peginterferon alfa-2a) were negative; long-term maintenance therapy did not halt liver disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/14\">",
"     14",
"    </a>",
"    ]. Currently, maintenance therapy is not recommended for nonresponders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link&amp;anchor=H6411393#H6411393\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\", section on 'Maintenance therapy in nonresponders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154559\">",
"    <span class=\"h1\">",
"     TREATMENT IN SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154826\">",
"    <span class=\"h2\">",
"     Recurrence after liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of HCV occurs in more than 95 percent of patients after liver transplantation. However, the therapeutic options are limited in this population, and rigorous clinical trials are difficult to conduct. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link&amp;anchor=H15#H15\">",
"     \"Liver transplantation for hepatitis C virus infection\", section on 'Treatment of recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154772\">",
"    <span class=\"h2\">",
"     Coinfection with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;All human immunodeficiency virus (HIV) infected patients should undergo screening for HCV. Treatment should be considered in these patients because coinfection is associated with an accelerated course of HCV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"     \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12154615\">",
"    <span class=\"h2\">",
"     Thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV infection in patients with thalassemia is common, with reported prevalences of anti-HCV antibodies in such patients of 4 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/15\">",
"     15",
"    </a>",
"    ]. Treatment in these patients may be complicated by the hemolysis associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , leading to worsening iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the American Society of Hematology recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      should be suggested to patients with HCV chronic hepatitis or compensated cirrhosis.",
"     </li>",
"     <li>",
"      Therapy should be administered for 48 weeks to patients infected by genotype 4 and for 24 weeks for patients infected by genotype 2 or 3.",
"     </li>",
"     <li>",
"      In patients infected with genotype 4, antiviral therapy should be withdrawn after 12 weeks if serum HCV RNA levels have not decreased by at least 2 log",
"      <sub>",
"       10",
"      </sub>",
"      compared with baseline.",
"     </li>",
"     <li>",
"      An increase in the number of blood transfusions during antiviral therapy may be required to maintain a hemoglobin level of more than 9",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The guidelines do not recommend the use of growth factors such as erythropoietin (which is already elevated in these patients).",
"     </li>",
"     <li>",
"      Intensification of chelation treatment before starting antiviral treatment should be considered in patients with severe iron burden. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of beta thalassemia\", section on 'Iron chelation therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"       \"Chelation therapy for iron overload states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical monitoring of liver disease is necessary in thalassemia patients with HCV chronic hepatitis or cirrhosis who have contraindications to antiviral therapy or have failed previous antiviral therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no guidelines about whether patients with a drop in hemoglobin during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    should have their ribavirin dose reduced. In one study of patients with thalassemia undergoing treatment for HCV, the dose of ribavirin was reduced if the patient's blood transfusion requirement doubled [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/600/abstract/16\">",
"     16",
"    </a>",
"    ]. Until additional data become available, we believe that it is reasonable to decrease the dose of ribavirin by 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in patients whose transfusion requirements double.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12153764\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of interferon (standard or pegylated) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , as well as their management, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60837661\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who achieve an SVR who do not have cirrhosis do not require any specific follow-up for their HCV, though some will check an HCV viral load one year after the completion of treatment to confirm that the patient has achieved an SVR. Patients who fail to achieve an SVR should be followed for signs of progression of their liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'General management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cirrhosis, regardless of whether they attain an SVR, require ongoing monitoring because they continue to be at risk of hepatocellular carcinoma&nbsp;and require ongoing surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/22/4451?source=see_link\">",
"       \"Patient information: Latest medicines for hepatitis C (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/35/30258?source=see_link\">",
"       \"Patient information: Treatment for hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12156966\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat a patient with chronic hepatitis C virus (HCV) infection is based upon several factors, including the natural history of the disease, the stage of fibrosis, and the efficacy and adverse effects related to therapy. In general, patients being considered for treatment should have histologic and virologic evidence of chronic HCV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=see_link\">",
"     \"Patient selection for antiviral therapy for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Genotype 2 or 3:",
"      </strong>",
"      For patients with genotype 2 or 3 who are candidates for therapy, we recommend treatment with peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (not weight-based) rather than treating with standard interferon and ribavirin or peginterferon monotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment with peginterferon plus ribavirin should be administered for 24 weeks in patients with genotype 2 or 3. (See",
"      <a class=\"local\" href=\"#H488640991\">",
"       'Treatment-naive patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12154514\">",
"       'Relapsers and nonresponders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H488644295\">",
"       'Doses of peginterferon and ribavirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Genotype 4:",
"      </strong>",
"      For patients with genotype 4 who are candidates for therapy, we recommend treatment with peginterferon and weight-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      rather than treating with standard interferon and ribavirin or peginterferon monotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Treatment with peginterferon plus weight-based ribavirin should be planned for 48 weeks, but the actual duration of therapy will be determined in part by the viral response. (See",
"      <a class=\"local\" href=\"#H488640991\">",
"       'Treatment-naive patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12154514\">",
"       'Relapsers and nonresponders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H488641848\">",
"       'Monitoring viral load during therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H488644295\">",
"       'Doses of peginterferon and ribavirin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Treatment should be discontinued in patients who do not achieve at least a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      reduction in HCV RNA at week 12 (ie, early virologic response).",
"     </li>",
"     <li>",
"      Patients who have at least a 2 log",
"      <sub>",
"       10",
"      </sub>",
"      reduction in HCV RNA but still have detectable HCV RNA at week 12 should be retested at week 24. Treatment should be discontinued if HCV RNA continues to be positive at week 24.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with chronic hepatitis C genotype 2, 3, or 4, we suggest treatment with peginterferon alfa-2a rather than peginterferon alfa-2b (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19310924\">",
"       'Choice of peginterferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients have their viral loads checked at baseline and at weeks 4, 12, and 24 of therapy to assess for a treatment response and to make decisions about continuing treatment or possibly altering the duration of treatment. Patients should also have a viral load checked 24 weeks after therapy is completed to assess for an SVR. (See",
"      <a class=\"local\" href=\"#H488641848\">",
"       'Monitoring viral load during therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/1\">",
"      Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/2\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/3\">",
"      Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006; 45:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/4\">",
"      McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/5\">",
"      Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 2007; 14:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/6\">",
"      Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009; 49:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/7\">",
"      Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/8\">",
"      Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/9\">",
"      Awad T, Thorlund K, Hauser G, et al; Cochrane Hepato-Biliary Group. Peginterferon alpha-2a may achieve higher sustained virological response than peginteferon alpha-2b in chronic hepatitis C: a Cochrane systematic review of randomized clinical trials. Hepatology 2009; 50(Suppl):707A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/10\">",
"      Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/11\">",
"      Flori N, Funakoshi N, Duny Y, et al. Pegylated Interferon-&alpha;2a and Ribavirin versus Pegylated Interferon-&alpha;2b and Ribavirin in Chronic Hepatitis C : A Meta-Analysis. Drugs 2013; 73:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/12\">",
"      Cheng SJ, Bonis PA, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/13\">",
"      Singal AG, Waljee AK, Shiffman M, et al. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010; 32:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/14\">",
"      Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/15\">",
"      Di Marco V, Capra M, Angelucci E, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 2010; 116:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/600/abstract/16\">",
"      Sood A, Sobti P, Midha V, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol 2010; 29:62.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15795 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-BA6E9C3E55-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_600=[""].join("\n");
var outline_f0_37_600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12156966\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12153729\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19315213\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488642015\">",
"      FACTORS ASSOCIATED WITH A RESPONSE TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488642863\">",
"      SELECTION OF PATIENTS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488641848\">",
"      MONITORING VIRAL LOAD DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19310924\">",
"      CHOICE OF PEGINTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488644295\">",
"      DOSES OF PEGINTERFERON AND RIBAVIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H488642654\">",
"      TREATMENT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H488640991\">",
"      Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H488642640\">",
"      - Genotype 2 or 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H488642647\">",
"      - Genotype 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12154514\">",
"      Relapsers and nonresponders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12154102\">",
"      - Prior treatment with standard interferon monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12154109\">",
"      - Prior treatment with standard interferon and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12154116\">",
"      - Prior treatment with peginterferon and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12158458\">",
"      MAINTENANCE THERAPY IN NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12154559\">",
"      TREATMENT IN SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12154826\">",
"      Recurrence after liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12154772\">",
"      Coinfection with HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12154615\">",
"      Thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12153764\">",
"      SIDE EFFECTS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60837661\">",
"      FOLLOW-UP AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12156966\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/22/4451?source=related_link\">",
"      Patient information: Latest medicines for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/35/30258?source=related_link\">",
"      Patient information: Treatment for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38841?source=related_link\">",
"      Patient selection for antiviral therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27990?source=related_link\">",
"      Response-guided therapy for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_37_601="Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States";
var content_f0_37_601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/601/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/601/contributors\">",
"     Elaine I Tuomanen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/601/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/601/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/37/601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    (",
"    <em>",
"     pneumococcus",
"    </em>",
"    ) is a leading cause of serious illness among children worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/1\">",
"     1",
"    </a>",
"    ]. Before universal infant immunization with pneumococcal conjugate vaccine in the United States,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    caused approximately 17,000 cases of invasive disease each year among children younger than five years of age, including 700 cases of meningitis and 200 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/1\">",
"     1",
"    </a>",
"    ]. It was the most frequent cause of bacteremia, bacterial pneumonia, bacterial meningitis, sinusitis, and acute otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 7-valent pneumococcal conjugate vaccine (PCV7) was added to the schedule of recommended vaccines for children younger than two years of age in the United States in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. PCV7 contains serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to a mutant of diphtheria toxoid (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ). The routine use of PCV7 resulted in a decreased incidence of invasive pneumococcal disease in children. However, there were increasing data to suggest that universal infant immunization with PCV7 changed the serotype patterns of invasive disease, nasopharyngeal (NP) colonization, and antibiotic resistance patterns. In 2010, a 13-valent pneumococcal conjugate vaccine replaced PCV7 in the routine childhood immunization schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of universal infant immunization with PCV7 and PCV13 on invasive serotypes, nasopharyngeal flora, and antibiotic resistance in children in the United States will be reviewed here. The impact in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link&amp;anchor=H3#H3\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\", section on 'Impact of childhood vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumococcal conjugate and polysaccharide vaccines also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) to the standard childhood immunization schedule has shown that the vaccine is effective in preventing invasive pneumococcal disease (IPD) and providing herd immunity (",
"    <a class=\"graphic graphic_figure graphicRef64834 \" href=\"UTD.htm?10/26/10658\">",
"     figure 1",
"    </a>",
"    ). In 2003, it was estimated that 29,599 cases of vaccine serotype IPD were prevented through routine immunization. Approximately two-thirds of these cases were prevented through herd immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/4\">",
"     4",
"    </a>",
"    ]. The greatest decline has been noted in pneumococcal bacteremia without a focus.",
"   </p>",
"   <p>",
"    The efficacy of universal infant immunization with PCV7 in the United States on the incidence of IPD in children and adults is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H8#H8\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Efficacy and effectiveness'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link&amp;anchor=H3#H3\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\", section on 'Impact of childhood vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9889776\">",
"    <span class=\"h1\">",
"     INVASIVE DISEASE CAUSED BY NON-VACCINE SEROTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance of pneumococcal isolates in children with invasive pneumococcal disease (IPD) indicates that, after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) to the routine childhood immunization schedule, there was an increase in the proportion of cases of IPD caused by nonvaccine serotypes (eg, replacement serotypes), including serotypes 19A, 6C, and 22F, and serogroups 15 and 33 (",
"    <a class=\"graphic graphic_figure graphicRef64834 \" href=\"UTD.htm?10/26/10658\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/4-22\">",
"     4-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the increase in IPD caused by nonvaccine serotypes was small compared with the overall decline in IPD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/4\">",
"     4",
"    </a>",
"    ]. Data from the CDC Active Bacterial Core (ABC) surveillance indicate that in 2003, there was an estimated increase of IPD caused by nonvaccine serotypes of 4721 cases, whereas there was an estimated decrease in IPD caused by vaccine serotypes of 29,599 cases: a net decline of 24,878 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/4\">",
"     4",
"    </a>",
"    ]. An increase in the proportion of IPD due to nonvaccine serotypes was noted in a number of other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/5-20\">",
"     5-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surveillance from eight children&rsquo;s hospitals in the United States following introduction of PCV13 in 2010 indicates that the most common non-PCV13 serotypes isolated from children hospitalized with IPD were 33F, 22F, 12, 15B, 15C, 23A, and 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These reports highlight the ability of pneumococcus to adapt to vaccine selective pressure and the need to remain vigilant for the invasive disease caused by nonvaccine serotypes. Factors other than the use of pneumococcal conjugate vaccines (eg, patterns of antibiotic use) may contribute to IPD epidemiology [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Serotype 19A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children, serotype 19A emerged as an important cause of IPD by replacement serotypes after the introduction of the 7-valent pneumococcal conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/16,22,27-29\">",
"     16,22,27-29",
"    </a>",
"    ]. Serotype 19A also emerged as an important cause of multidrug-resistant acute otitis media, coalescent mastoiditis, and chronic sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Serotype 19A is included in the 13-valent pneumococcal conjugate vaccine that was licensed in 2010. Surveillance from eight children&rsquo;s hospitals in the United States following introduction of PCV13 in 2010 demonstrated a 58 percent decline in IPD due to serotype 19A among hospitalized children; but 19A remained the most frequently isolated serotype [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H16#H16\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H6#H6\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Other vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NASOPHARYNGEAL FLORA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the effects of universal immunization with the 7-valent pneumococcal conjugate vaccine (PCV7) on nasopharyngeal (NP) carriage have shown that vaccination does not change the overall rate of pneumococcal carriage [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/20,34-38\">",
"     20,34-38",
"    </a>",
"    ]. However, it does reduce the acquisition of vaccine serotypes and increases the acquisition of nonvaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/7,20,35-48\">",
"     7,20,35-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PCV7 serotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjugate vaccines reduce NP carriage of the serotypes included in the vaccine (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/35-37,39-43,47,48\">",
"     35-37,39-43,47,48",
"    </a>",
"    ]. This was demonstrated in several pre-licensure investigations of small cohorts of children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], and in post-licensure surveillance of children in Massachusetts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 275 children (2 to 24 months of age) underwent NP cultures at well-child and acute-care visits for acute otitis media between 2000 and 2003 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/42\">",
"       42",
"      </a>",
"      ]. During this time period, NP colonization with PCV7 vaccine serotypes decreased from 22 to 2 percent.",
"     </li>",
"     <li>",
"      In another report, NP cultures were obtained from children &lt;7 years of age at well-child and acute-care visits in primary care practices in Massachusetts communities between 2001 and 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/35,38,48\">",
"       35,38,48",
"      </a>",
"      ]. NP colonization with PCV7 vaccine serotypes decreased from 36 to 2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunization of preschool children with conjugate vaccines also may provide herd immunity to their younger siblings. In a randomized trial, 262 toddlers (aged 12 to 35 months of age) attending day care centers were assigned to receive a 9-valent pneumococcal conjugate vaccine (PCV9) (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ) or meningococcal conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/41\">",
"     41",
"    </a>",
"    ]. NP cultures were assessed at monthly or bimonthly intervals for the first two years of the study. NP cultures also were assessed at monthly intervals in 46 of the subjects' younger siblings who were not attending day care. Fewer siblings of PCV9 recipients had NP cultures positive for vaccine serotypes than siblings of controls (21 versus 34 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Non-PCV7 serotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the inhibitory effect on vaccine serotypes, pneumococcal vaccination in children is associated with increases in the nasal carriage of nonvaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/20,35-38,40-47\">",
"     20,35-38,40-47",
"    </a>",
"    ]. In the Massachusetts surveillance studies described above, NP carriage of nonvaccine serotypes increased from 7 to 16 percent in children 2 to 24 months of age between 2000 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/42\">",
"     42",
"    </a>",
"    ] and from 15 to 29 percent in children &lt;7 years of age between 2001 and 2007, with significant increases in serotypes 19A, 35B, 23A, and 7F [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/38\">",
"     38",
"    </a>",
"    ]. The most common nonvaccine serotypes colonizing the NP of the older children were 11, 15, and 29.",
"   </p>",
"   <p>",
"    Post-hoc analysis of a large randomized trial on the effect of PCV7 on pneumococcal carriage indicated that nasopharyngeal acquisition of serotype 19A was increased among children who received PCV7 at 2, 4, and 11 months compared with those who were unvaccinated (16.2 versus 9.2 percent, relative risk 1.75, 95% CI 1.14-2.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/49\">",
"     49",
"    </a>",
"    ]. The proportion of children who had used antibiotics in the six months before nasopharyngeal culture was similar between groups. The clonal distribution of the nasopharyngeal isolates was similar to that of serotype 19A invasive isolates.",
"   </p>",
"   <p>",
"    A similar increase in colonization with nonvaccine serotypes has been noted among the younger siblings of PCV9 recipients. In the day care trial described above, a greater proportion of siblings of PCV9 recipients than siblings of control vaccine recipients had NP cultures positive for nonvaccine serotypes (19 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical implications of these changes in NP colonization remain to be determined. The effect of colonization with nonvaccine serotypes, some of which are penicillin-resistant, will depend upon the ability of the new serotypes to cause local (eg, otitis media) or invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/44,50\">",
"     44,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal carriage of",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    in children appears to be inversely related to NP carriage of pneumococcal vaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. A potential concern with",
"    <em>",
"     S. aureus",
"    </em>",
"    carriage is the increasing frequency of community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'CA-MRSA infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Herd effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization of children with PCV7 has been effective in reducing IPD in vaccinated children and, indirectly, in unvaccinated adults (",
"    <a class=\"graphic graphic_figure graphicRef64834 \" href=\"UTD.htm?10/26/10658\">",
"     figure 1",
"    </a>",
"    ). Similarly, immunization of children with PCV7 appears to have indirect effects on the nasopharyngeal colonization of unvaccinated household contacts and community members [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/47,53,54\">",
"     47,53,54",
"    </a>",
"    ]. Evaluation of household members of children who participated in a trial of PCV7 found that adults and unvaccinated children (&lt;5 years) who were contacts of vaccinees were less likely to be colonized with vaccine serotypes than contacts of controls. However, they had an increase in colonization with nonvaccine serotypes (similar to the effects seen in vaccinated children, as described above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resistance of pneumococci to a variety of antimicrobial agents has become a worldwide health problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"    </a>",
"    .) The effects of routine 7-valent pneumococcal conjugate vaccine (PCV7) immunization in the United States on antibiotic susceptibility patterns of invasive and NP isolates are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Invasive isolates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from Active Bacterial Core surveillance areas in the US indicate that penicillin-nonsusceptible rates of invasive pneumococcal disease (IPD) among children younger than five years declined by 64 percent between 1998-1999 and 2007-2008 (ie, before and after the introduction of PCV7, respectively; but before replacement of PCV7 with PCV13 in 2010) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/55\">",
"     55",
"    </a>",
"    ]. Rates of IPD nonsusceptible to multiple antibiotics also declined (",
"    <a class=\"graphic graphic_figure graphicRef54045 \" href=\"UTD.htm?33/44/34511\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    During 2007-2008, the six serotypes in PCV13, but not in PCV7 (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ) (almost exclusively serotype 19A) accounted for 97 percent of penicillin-nonsusceptible IPD among children younger than five years, suggesting potential for further decline in rates of penicillin-nonsusceptible IPD with the routine use of PCV13. Surveillance from eight children&rsquo;s hospitals in the United States found a decline in the proportion of isolates nonsusceptible to penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    after the introduction of PCV13 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/23\">",
"     23",
"    </a>",
"    ]. Susceptibility results for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    were unchanged.",
"   </p>",
"   <p>",
"    Two factors are thought to be responsible for the reduction in antibiotic-resistant strains in the pneumococcal conjugate vaccine era [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/41,56\">",
"     41,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunization with PCV decreases acquisition of vaccine serotypes that are antibiotic-resistant",
"     </li>",
"     <li>",
"      Recipients of PCV receive less antibiotic therapy than nonvaccinated children, further reducing the selective pressure to acquire resistant strains",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continued surveillance is necessary. In population-based surveillance during 2007, serotypes 15A, 23A, 35B, and 6C (which are not included in PCV13) accounted for 32 percent of invasive isolates nonsusceptible to penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     NP isolates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal vaccination of infants appears to have an effect on the antibiotic resistance of strains carried in the nasopharynx as well as on those causing invasive disease. However, the effects are inconsistent, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cross-sectional survey in children 3 to 59 months in Anchorage, Alaska, noted a decrease in the NP carriage of pneumococcal isolates nonsusceptible to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      from 44 to 16 percent between 2000 and 2004, but no change in the NP carriage of strains nonsusceptible to penicillin (approximately 36 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/37\">",
"       37",
"      </a>",
"      ]. Among strains nonsusceptible to penicillin, there was an increase in the proportion of serotype 19A (from 10 to 32 percent).",
"     </li>",
"     <li>",
"      A report from St. Louis, Missouri, noted a decrease in the prevalence of pneumococcal isolates nonsusceptible to penicillin in the NP cultures of children &lt;7 years with acute respiratory infections (from 25 to 12 percent between 2000 and 2004) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surveillance of Massachusetts children &lt;7 years found that overall NP carriage of penicillin-nonsusceptible pneumococci was similar between 2001 and 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/48\">",
"       48",
"      </a>",
"      ]. However, penicillin nonsusceptibility increased among serotypes contained in PCV13 (particularly 19A). Multilocus sequence typing of isolates demonstrated expansion of previously recognized clones of nonvaccine serotypes (eg, 19A, 15A, and 35B), emergence of new clones, and serotype switching, but no evidence of de novo acquisition of resistance. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Non-PCV7 serotypes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inconsistency of the above observations suggests that factors other than immunization with PCV7 may play a role in the antibiotic susceptibility patterns of pneumococcal isolates from the nasopharynx. The increased use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    may be one such factor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These reports highlight the need to continue to monitor the antibiotic resistance patterns of strains of pneumococcus carried in the nasopharynx and the use of antibiotics with potential to promote multidrug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     VACCINE LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of pneumococcal conjugate vaccines in children has reduced the incidence of invasive pneumococcal disease. However, the issue of eliminating noninvasive disease remains critical. Even if the vaccines as currently formulated substantially decrease the incidence of upper respiratory infection, the effect is not likely to be permanent.",
"   </p>",
"   <p>",
"    The hallmark of pneumococci is their ease of natural DNA transformation as evidenced by the diversity and rapidity of spread of antibiotic resistance. As has been demonstrated, a strain can enter a day care center as one serotype and acquire another serotype capsule within just a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The molecular flexibility in the capsular locus is based upon its modular gene structure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/61\">",
"     61",
"    </a>",
"    ]. There are no known limits to capsular exchangeability. Under antibody selective pressure, pneumococci can be expected to quickly evolve to circumvent vaccines that contain a limited number of serotypes. As described above, there are data to suggest this process may have begun. The only long-term solution to this problem is the development of a vaccine containing one or several protective protein antigens from pneumococcus, rather than serogroup-specific polysaccharide antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/601/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of invasive pneumococcal disease (IPD) in the United States has declined dramatically since the pneumococcal conjugate vaccine was added to the routine childhood immunization schedule (",
"      <a class=\"graphic graphic_figure graphicRef64834 \" href=\"UTD.htm?10/26/10658\">",
"       figure 1",
"      </a>",
"      ). The greatest decline has been noted in pneumococcal bacteremia without a focus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The large decline in cases of IPD caused by PCV7 vaccine serotypes (",
"      <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"       table 1",
"      </a>",
"      ) was accompanied by a small increase in the number of cases of IPD caused by nonvaccine serotypes (eg, replacement serotypes) (",
"      <a class=\"graphic graphic_figure graphicRef64834 \" href=\"UTD.htm?10/26/10658\">",
"       figure 1",
"      </a>",
"      ). Most of the replacement serotypes are included in PCV13, which has replaced PCV7 in the United States. (See",
"      <a class=\"local\" href=\"#H9889776\">",
"       'Invasive disease caused by non-vaccine serotypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Widespread use of PCV7 was associated with an increase in the proportion of cases of IPD associated with pneumonia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      empyema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=see_link\">",
"       \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=see_link&amp;anchor=H8#H8\">",
"       \"Pneumococcal pneumonia in children\", section on 'Effusion/empyema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among children receiving the 7-valent vaccine, serotype 19A was an important cause of IPD by replacement serotypes. Serotype 19A is included in the 13-valent pneumococcal conjugate vaccine introduced in 2010. However, it remains an important cause of IPD. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Serotype 19A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Universal infant immunization does not appear to have affected the overall rate of carriage of pneumococcus in the nasopharynx. However, universal immunization has reduced carriage of vaccine serotypes and increased carriage of nonvaccine serotypes and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      . The clinical implications of these changes in nasopharyngeal colonization remain to be determined. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nasopharyngeal flora'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Universal infant immunization has been associated with a decrease in the rate of penicillin-nonsusceptible and multiple antibiotic-nonsusceptible IPD (",
"      <a class=\"graphic graphic_figure graphicRef54045 \" href=\"UTD.htm?33/44/34511\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Invasive isolates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data regarding the effects of universal infant immunization on the antibiotic resistance patterns of isolates from the nasopharynx are inconsistent. Resistance may be increased through the expansion of clones of antibiotic-resistant nonvaccine serotypes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'NP isolates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/1\">",
"      Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/2\">",
"      American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/5\">",
"      Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/6\">",
"      Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/7\">",
"      Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/8\">",
"      Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/9\">",
"      Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/10\">",
"      Schutze GE, Tucker NC, Mason EO Jr. Impact of the conjugate pneumococcal vaccine in arkansas. Pediatr Infect Dis J 2004; 23:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/12\">",
"      Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008; 47:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/13\">",
"      Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/14\">",
"      Park IH, Moore MR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008; 198:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/15\">",
"      Carvalho Mda G, Pimenta FC, Gertz RE Jr, et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 2009; 47:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/16\">",
"      Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/17\">",
"      Byington CL, Hulten KG, Ampofo K, et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol 2010; 48:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/18\">",
"      Hsu KK, Shea KM, Stevenson AE, et al. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010; 29:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/19\">",
"      Techasaensiri C, Messina AF, Katz K, et al. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr Infect Dis J 2010; 29:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/20\">",
"      Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/21\">",
"      Green MC, Mason EO, Kaplan SL, et al. Increase in prevalence of Streptococcus pneumoniae serotype 6C at Eight Children's Hospitals in the United States from 1993 to 2009. J Clin Microbiol 2011; 49:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/22\">",
"      Yildirim I, Stevenson A, Hsu KK, Pelton SI. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J 2012; 31:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/23\">",
"      Kaplan SL, Barson WJ, Lin PL, et al. Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J 2013; 32:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/24\">",
"      Black S. Changing epidemiology of invasive pneumococcal disease: a complicated story. Clin Infect Dis 2008; 47:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/25\">",
"      Fenoll A, Aguilar L, Granizo JJ, et al. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? J Antimicrob Chemother 2008; 62:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/26\">",
"      Moore MR. Rethinking replacement and resistance. J Infect Dis 2009; 199:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/27\">",
"      Pai R, Moore MR, Pilishvili T, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005; 192:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae--Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 2007; 56:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/29\">",
"      Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010; 125:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/30\">",
"      Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/31\">",
"      Ongkasuwan J, Valdez TA, Hulten KG, et al. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008; 122:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/32\">",
"      Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg Infect Dis 2009; 15:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/33\">",
"      McNeil JC, Hulten KG, Mason EO Jr, Kaplan SL. Serotype 19A is the most common Streptococcus pneumoniae isolate in children with chronic sinusitis. Pediatr Infect Dis J 2009; 28:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/34\">",
"      Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr Infect Dis J 2005; 24:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/35\">",
"      Huang SS, Platt R, Rifas-Shiman SL, et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116:e408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/36\">",
"      Millar EV, O'Brien KL, Watt JP, et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006; 43:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/37\">",
"      Park SY, Moore MR, Bruden DL, et al. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J 2008; 27:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/38\">",
"      Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009; 124:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/39\">",
"      Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/40\">",
"      Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/41\">",
"      Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003; 22:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/42\">",
"      Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004; 23:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/43\">",
"      Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/44\">",
"      Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007; 195:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/45\">",
"      O'Brien KL, Millar EV, Zell ER, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007; 196:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/46\">",
"      Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 2009; 199:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/47\">",
"      van Gils EJ, Veenhoven RH, Hak E, et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 2009; 302:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/48\">",
"      Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J 2012; 31:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/49\">",
"      van Gils EJ, Veenhoven RH, Hak E, et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 2010; 304:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/50\">",
"      Long SS. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 2005; 41:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/51\">",
"      Regev-Yochay G, Dagan R, Raz M, et al. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA 2004; 292:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/52\">",
"      Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004; 363:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/53\">",
"      Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008; 47:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/54\">",
"      Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/55\">",
"      Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/56\">",
"      Klugman KP. Vaccination: a novel approach to reduce antibiotic resistance. Clin Infect Dis 2004; 39:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/57\">",
"      Gertz RE Jr, Li Z, Pimenta FC, et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010; 201:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/58\">",
"      Garbutt J, Rosenbloom I, Wu J, Storch GA. Empiric first-line antibiotic treatment of acute otitis in the era of the heptavalent pneumococcal conjugate vaccine. Pediatrics 2006; 117:e1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/59\">",
"      Greenberg D, Givon-Lavi N, Sharf AZ, et al. The association between antibiotic use in the community and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Bedouin children. Pediatr Infect Dis J 2008; 27:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/60\">",
"      Nesin M, Ramirez M, Tomasz A. Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo. J Infect Dis 1998; 177:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/61\">",
"      Caimano MJ, Hardy GG, Yother J. Capsule genetics in Streptococcus pneumoniae and a possible role for transposition in the generation of the type 3 locus. Microb Drug Resist 1998; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/601/abstract/62\">",
"      Lee CJ, Banks SD, Li JP. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Crit Rev Microbiol 1991; 18:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6019 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_601=[""].join("\n");
var outline_f0_37_601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9889776\">",
"      INVASIVE DISEASE CAUSED BY NON-VACCINE SEROTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Serotype 19A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NASOPHARYNGEAL FLORA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PCV7 serotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Non-PCV7 serotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Herd effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANTIBIOTIC RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Invasive isolates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NP isolates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      VACCINE LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6019|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/26/10658\" title=\"figure 1\">",
"      Rates of IPD after PCV7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/44/34511\" title=\"figure 2\">",
"      Nonsusceptibility invasive pneumococcal isolates children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/59/15293\" title=\"table 1\">",
"      Pneumococcal vaccines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/34/9770?source=related_link\">",
"      Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=related_link\">",
"      Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=related_link\">",
"      Pneumococcal pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_37_602="Hereditary neuropathies associated with generalized disorders";
var content_f0_37_602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary neuropathies associated with generalized disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/602/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/602/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/602/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/602/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/37/602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/37/602/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/37/602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hereditary peripheral neuropathies have been classified based upon clinical characteristics, mode of inheritance, electrophysiologic features, metabolic defect, and, more recently, specific genetic markers. The primary hereditary neuropathies predominantly affect peripheral nerves and produce symptoms of peripheral nerve dysfunction. Other hereditary neuropathies affect both the central and peripheral nervous systems and, in some cases, other organs; in such patients, symptoms related to the peripheral neuropathy may be overshadowed by additional manifestations of the disease (",
"    <a class=\"graphic graphic_table graphicRef74269 graphicRef72307 graphicRef56567 graphicRef52324 \" href=\"UTD.htm?11/20/11584\">",
"     table 1A-D",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The last group of disorders is reviewed here. The primary motor-sensory and sensory&ndash;autonomic neuropathies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21258726\">",
"    <span class=\"h1\">",
"     SPINOCEREBELLAR ATAXIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spinocerebellar ataxias (SCA) are a heterogeneous group of inherited disorders with different neuropathological profiles reflecting the degree of cerebellar and brainstem dysfunction or degeneration. A peripheral neuropathy is described in some but not all (",
"    <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"     table 1A",
"    </a>",
"    ). Peripheral neuropathy has been best characterized in SCA type 4, in which a prominent axonal neuropathy is present [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/1\">",
"     1",
"    </a>",
"    ]. A mild peripheral neuropathy with decreased deep tendon reflexes and reduced vibration sense has been described in type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/2\">",
"     2",
"    </a>",
"    ], type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/3\">",
"     3",
"    </a>",
"    ], type 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/4\">",
"     4",
"    </a>",
"    ], and type 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed review of the spinocerebellar ataxias is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link\">",
"     \"The spinocerebellar ataxias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFANTILE NEUROAXONAL DYSTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile neuroaxonal dystrophy (INAD; MIM 256600), also called PLA2G6-associated neurodegeneration or Seitelberger disease, is an autosomal recessive disorder. It is considered one of several subtypes of neurodegeneration with brain iron accumulation (NBIA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"     \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classification of infantile neuroaxonal dystrophy has been evolving since the discovery that nearly 80 percent of children with infantile neuroaxonal dystrophy have mutations in the PLA2G6 gene with a locus on chromosome 22q13.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Mutations in the PLA2G6 gene have also been detected in patients previously diagnosed with other subtypes of NBIA, and it now appears that the PLA2G6 mutation is associated with a characteristic clinical and radiologic phenotype called PLA2G6-associated neurodegeneration (PLAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with infantile neuroaxonal dystrophy typically present by two to three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/9\">",
"     9",
"    </a>",
"    ]. In a series of 14 children with PLAN, the median age of symptom presentation was 14 months (range 12 to 22 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/7\">",
"     7",
"    </a>",
"    ]. Of these, five died at median age of nine years (range 6.5 to 14 years).",
"   </p>",
"   <p>",
"    Symptoms related to infantile neuroaxonal dystrophy reflect involvement of the peripheral nerves, central nervous system, and autonomic nervous system (",
"    <a class=\"graphic graphic_table graphicRef72307 \" href=\"UTD.htm?31/28/32204\">",
"     table 1B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The peripheral neuropathy is characterized by loss of distal sensation, which may lead to limb mutilation and muscle atrophy. Hypotonia and loss of motor milestones are associated with early onset of the disease. Deep tendon reflexes typically are hypoactive.",
"   </p>",
"   <p>",
"    Central nervous system manifestations include cognitive deterioration, spasticity, optic atrophy, and hypothalamic dysfunction with diabetes insipidus and hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/11\">",
"     11",
"    </a>",
"    ]. Autonomic symptoms may include urinary retention, decreased tearing, and dysfunction of temperature regulation. Early studies reported rare seizures in children with late-onset neuroaxonal dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/12\">",
"     12",
"    </a>",
"    ], but seizures have not been reported in children with PLA2G6 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electromyography shows signs of chronic denervation; fast rhythms may be present on electroencephalography, and visual evoked potentials are usually abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) may be suggestive of the diagnosis. Cerebellar atrophy and gliosis is universally present, with increased signal on fluid-attenuated inversion recovery (FLAIR) and T2-weighted MRI sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/7,10,13\">",
"     7,10,13",
"    </a>",
"    ]. Other common MRI findings include hypointensity of the globus pallidus, dentate nuclei, and substantia nigra on high susceptibility gradient echo (T2*) sequences, and hypointensity of the globus pallidus on fast spin echo sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/7,14\">",
"     7,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic findings, which are seen best by electron microscopy, are similar in the peripheral, central, and autonomic nervous systems. Spheroids containing mitochondria, glycogen-like granules, and dense bodies occur in both central and peripheral nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Spheroid formation leads to axonal swelling.",
"   </p>",
"   <p>",
"    Other abnormalities in the central nervous system include cerebellar atrophy with neuronal atrophy and astrogliosis and involvement of the corticospinal tracts. Immunohistochemistry reveals the presence of ubiquitin but not beta-tuberculin or beta-amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/17\">",
"     17",
"    </a>",
"    ]. These findings suggest that loss of microtubule function is part of the mechanism of spheroid formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of infantile neuroaxonal dystrophy is suggested by the progressive neurologic symptoms beginning in infancy, but further testing is required to establish the diagnosis.",
"   </p>",
"   <p>",
"    The diagnosis of infantile neuroaxonal dystrophy generally is confirmed by the demonstration of spheroids on peripheral nerve or conjunctival biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/9,15,18\">",
"     9,15,18",
"    </a>",
"    ]. An abnormal conjunctival biopsy is not dependent upon the presence of optic atrophy. Where available, PLA2G6 mutation analysis may confirm the diagnosis in patients with PLA2G6-associated neurodegeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of infantile neuroaxonal dystrophy includes other subtypes of NBIA, as these exhibit broad phenotypic overlap. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"     \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TANGIER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tangier disease is an autosomal codominant condition in which homozygotes have no serum high density lipoprotein (HDL) and heterozygotes have serum HDL concentrations of approximately one-half of those in normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/19\">",
"     19",
"    </a>",
"    ]. HDL-mediated cholesterol efflux from macrophages and intracellular lipid trafficking are impaired in this disorder, leading to the presence of foam cells in macrophages and other cells of the reticuloendothelial system throughout the body (",
"    <a class=\"graphic graphic_table graphicRef72307 \" href=\"UTD.htm?31/28/32204\">",
"     table 1B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defect in Tangier disease appears to involve mutations in the ATP-binding cassette transporter A1 (ABCA1) gene on chromosome 9q31, which encodes for the cholesterol efflux regulatory protein [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/19,21-24\">",
"     19,21-24",
"    </a>",
"    ]. ABCA1 appears to play a central role in intracellular cholesterol transport and is associated with increased HDL catabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. One suggestion is that reduced cholesterol efflux onto nascent HDL particles leads to lipid depleted particles that are then rapidly catabolized [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link&amp;anchor=H4#H4\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\", section on 'HDL metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homozygotes develop cholesterol ester deposition in tonsils (orange tonsils), liver, spleen, gastrointestinal tract, lymph nodes, bone marrow, and Schwann cells. The main clinical manifestations are hepatosplenomegaly and premature coronary disease; a neuropathy occurs in at least 50 percent of patients and is the most debilitating feature of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/20\">",
"     20",
"    </a>",
"    ]. In a review in which the findings in 51 patients with homozygous Tangier disease were compared to over 3,000 controls, the patients were more likely to have both peripheral neuropathy (54 versus &lt;1 percent) and cardiovascular disease, defined as angina, myocardial infarction, or stroke (20 versus 5 percent overall and 44 versus 7 percent in those between the ages of 35 and 65) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two major types of neurologic syndromes are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A peripheral neuropathy occurs in childhood with fluctuating numbness, tingling, distal sensory loss, and distal weakness with muscle atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progressive loss of sensory and motor function in the upper body in a pattern similar to that which occurs in syringomyelia (a cystic degeneration of the spinal cord) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major pathologic findings on nerve biopsy are loss of smaller myelinated and unmyelinated nerve fibers and lipid vacuole accumulation in Schwann cells. The cause of nerve death is unknown, but nerve loss appears to precede the development of the lipid-laden Schwann cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of a low-fat diet may reduce the number of abnormal particles and can be associated with symptomatic improvement in the peripheral neuropathy. The administration of drugs that can increase serum HDL in other patients (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , niacin, or a statin) has little effect in those with Tangier disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/20\">",
"     20",
"    </a>",
"    ]. Possible future therapies involve pharmacologic manipulation of the reverse cholesterol transport pathway such as increasing cellular ABC1 expression to augment cellular efflux of cholesterol to HDL; preventing the catabolism of HDL without interfering with its cholesterol transport function; or increasing the rate of hepatic HDL cholesterol uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ABETALIPOPROTEINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abetalipoproteinemia (Bassen-Kornzweig syndrome) is reviewed here briefly and discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33833?source=see_link&amp;anchor=H1983214#H1983214\">",
"     \"Neuroacanthocytosis\", section on 'Abetalipoproteinemia'",
"    </a>",
"    ). It is a rare autosomal recessive disorder caused by mutations in the microsomal triglyceride transfer protein. The neurologic manifestations result from the inability to absorb and transport vitamin E and include progressive ataxia, sensory-motor neuropathy, and vision impairment with retinitis pigmentosa. Other clinical manifestations include acanthocytosis along with fat malabsorption and steatorrhea.",
"   </p>",
"   <p>",
"    The diagnosis is made in the setting of the typical clinical findings accompanied by laboratory findings of acanthocytosis, very low triglyceride and total cholesterol levels, and absent beta-lipoproteins. Neurologic manifestations can be prevented and partially reversed with the administration of vitamin E (150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) along with other fat soluble vitamins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33833?source=see_link&amp;anchor=H1983214#H1983214\">",
"     \"Neuroacanthocytosis\", section on 'Abetalipoproteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REFSUM DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refsum disease (MIM #266500), previously known as hereditary motor and sensory neuropathy IV, is a disorder of peroxisomal function. Peroxisomes are subcellular organelles that catalyze numerous functions in cellular metabolism. A group of genetic diseases in which impairment in one or more peroxisomal functions exists is expanding. The peroxisomal disorders usually are classified into three groups according to the presence or absence of intact peroxisomes and whether one or more than one peroxisomal enzyme or function is affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Refsum disease has been classified into classic and infantile forms; both are associated with abnormal phytanic acid accumulation. Classic Refsum disease (heredopathia atactica polyneuritiformis) is an autosomal recessive disorder associated with the accumulation of phytanic acid in plasma and tissues. Phytanic acid is a branched-chain fatty acid present in the typical human diet. Normally it is metabolized by activation to its CoA ester, phytanoyl-CoA and then alpha-oxidation to pristanic acid (",
"    <a class=\"graphic graphic_table graphicRef72307 \" href=\"UTD.htm?31/28/32204\">",
"     table 1B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H40#H40\">",
"     \"Peroxisomal disorders\", section on 'Refsum disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Refsum disease are unable to degrade phytanic acid because of deficient activity of phytanoyl-CoA hydroxylase (PhyH), a peroxisomal enzyme that catalyzes the first step of phytanic acid alpha-oxidation; this abnormality is caused by mutations in the PHYH gene that lead to an enzymatically inactive PhyH protein.",
"   </p>",
"   <p>",
"    A small number of patients with classic adult Refsum disease have defects involving the PEX7 gene rather than the PhyH gene. The PEX7 gene encodes the peroxin 7 receptor protein, which is required for peroxisomal import of proteins, and which plays a role in the incorporation of PhyH into peroxisomes. Defects in the PEX7 gene are also found in another hereditary disorder, rhizomelic chondrodysplasia punctata type 1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H34#H34\">",
"     \"Peroxisomal disorders\", section on 'Rhizomelic chondrodysplasia punctata type 1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A different defect is present in infantile Refsum disease, which is one of a group of lethal peroxisome biogenesis disorders (the others being Zellweger syndrome and neonatal adrenoleukodystrophy). This disorder is characterized by mutations in PEX1 or PEX6, which encode for members of the AAA protein family (ATPases associated with multiple cellular activities). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H29#H29\">",
"     \"Peroxisomal disorders\", section on 'Infantile Refsum disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of onset varies, but most patients are symptomatic by 20 years of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H40#H40\">",
"     \"Peroxisomal disorders\", section on 'Refsum disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classic Refsum disease is characterized by the presence of four clinical abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retinitis pigmentosa",
"     </li>",
"     <li>",
"      Peripheral polyneuropathy",
"     </li>",
"     <li>",
"      Cerebellar ataxia",
"     </li>",
"     <li>",
"      Elevated cerebrospinal fluid protein concentration (100 to 600",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      without an increase in cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Affected patients also may have sensorineural deafness, ichthyosis, anosmia, and cardiac conduction defects. Nerve conduction studies typically show a slowed conduction velocity. Peripheral nerve biopsy reveals hypertrophic changes with onion bulb formation and paracrystalline inclusions on electron microscopy.",
"   </p>",
"   <p>",
"    The diagnosis usually is made clinically and can be confirmed by measurement of serum phytanic acid concentrations. Strict reduction in dietary phytanic acid intake may be associated with a significant improvement in the clinical manifestations in patients with classic Refsum disease. Another method to reduce serum phytanic acid in these patients is plasmapheresis, which can be performed serially if necessary.",
"   </p>",
"   <p>",
"    Refsum disease is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H40#H40\">",
"     \"Peroxisomal disorders\", section on 'Refsum disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21258209\">",
"    <span class=\"h1\">",
"     CHEDIAK-HIGASHI SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chediak-Higashi syndrome (CHS) is an autosomal recessive disorder characterized by recurrent infections, partial albinism, hepatosplenomegaly, an increased risk of lymphoreticular malignancy, and multiple neurologic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=see_link\">",
"     \"Chediak-Higashi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who survive early childhood despite serious infections develop severe neurologic manifestations in adolescence and early adulthood. Both the peripheral and central nervous systems are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Neurologic features may include nystagmus, photosensitivity, seizures, mental retardation, generalized weakness, spinocerebellar degeneration, and parkinsonism. Biopsy of peripheral nerves reveals perivascular intracytoplasmic inclusions, loss of myelinated sensory fibers, and the presence of peroxidase positive granules in Schwann cells, similar to those seen in leukocytes, which are thought to be giant lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/32,35,36\">",
"     32,35,36",
"    </a>",
"    ]. Muscle biopsy reveals neurogenic atrophy with peroxidase positive granules similar to those seen in leukocytes.",
"   </p>",
"   <p>",
"    Patients who do not die from infection eventually enter the accelerated phase of the disease characterized by massive lymphohistiocytic infiltration of virtually all organ systems. Treatment with hematopoietic cell transplantation prevents infections and the accelerated phase, but patients still develop neurologic deficits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=see_link&amp;anchor=H9#H9\">",
"     \"Chediak-Higashi syndrome\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=see_link&amp;anchor=H10#H10\">",
"     \"Chediak-Higashi syndrome\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LYSOSOMAL STORAGE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lysosomes are acidic cellular organelles that function as terminal degradative compartments. Lysosomal storage diseases are a group of approximately 36 heterogeneous disorders characterized by the accumulation of undigested macromolecules within the lysosomes. They result from a deficiency of a specific lysosomal enzyme or protein, although how the accumulated substrates relate to the observed pathology is not known. Many are associated with a neurodegenerative phenotype, and a peripheral neuropathy occurs in Fabry disease, Krabbe disease, metachromatic leukodystrophy, and Niemann-Pick disease (",
"    <a class=\"graphic graphic_table graphicRef56567 \" href=\"UTD.htm?36/27/37308\">",
"     table 1C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fabry disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fabry disease (also called angiokeratoma corporis diffusum, ceramide trihexosidosis, and Anderson-Fabry disease) is an X-linked recessive glycolipid storage disease. The clinical manifestations, diagnosis and treatment of Fabry disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=see_link\">",
"     \"Neurologic manifestations of Fabry disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Krabbe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive disorder caused by the deficiency of galactocerebrosidase (GALC). The genetics, clinical manifestations, diagnosis and treatment of Krabbe disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=see_link\">",
"     \"Krabbe disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Metachromatic leukodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metachromatic leukodystrophy (MLD, sulfatide lipidosis) is an autosomal recessive lysosomal storage disease that occurs in 1 of 40,000 births. The genetics, clinical manifestations, diagnosis and treatment of Metachromatic leukodystrophy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=see_link\">",
"     \"Metachromatic leukodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Niemann-Pick disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niemann-Pick disease (NPD, sphingomyelin-cholesterol lipidosis) is a group of autosomal recessive disorders associated with splenomegaly, variable neurologic deficits, and the storage of sphingomyelin. The different types of Niemann-Pick disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=see_link\">",
"     \"Overview of Niemann-Pick disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MITOCHONDRIAL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in structure or function of mitochondria, mainly involving the oxidative phosphorylation, mitochondrial biogenesis and other metabolic pathways, are associated with a wide spectrum of clinical phenotypes. Peripheral neuropathy is a prominent feature in several (",
"    <a class=\"graphic graphic_table graphicRef52324 \" href=\"UTD.htm?39/16/40204\">",
"     table 1D",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Leigh syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leigh syndrome (subacute necrotizing encephalomyelopathy) is an inherited neurodegenerative disorder of infancy or childhood. It is characterized by developmental delay or psychomotor regression, signs of brainstem dysfunction, ataxia, dystonia, external ophthalmoplegia, seizures, lactic acidosis, vomiting, and weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Peripheral neuropathy with reduced nerve conduction velocity and demyelination also are frequent findings [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The prognosis is poor, with survival typically being a matter of months after disease onset.",
"   </p>",
"   <p>",
"    The pathologic hallmarks are bilateral, symmetric necrotizing lesions with spongy changes and microcysts in the basal ganglia, thalamus, brainstem, and spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/38\">",
"     38",
"    </a>",
"    ]. The mammary bodies are spared. Magnetic resonance imaging shows abnormal white matter signal in the putamen, basal ganglia, and brainstem with T2 images.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotype of Leigh syndrome appears to be related to altered mitochondrial metabolism. Alterations in the mitochondrial respiratory chain complex I [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/42-44\">",
"     42-44",
"    </a>",
"    ], pyruvate dehydrogenase complex (PDHC) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/45-47\">",
"     45-47",
"    </a>",
"    ] or in mitochondrial DNA (mtDNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/45,47,48\">",
"     45,47,48",
"    </a>",
"    ] have been associated with autosomal, X-linked, or mtDNA mutations (maternally-inherited Leigh syndrome). A deficiency in cytochrome c oxidase (COX), the fourth multisubunit complex of the respiratory chain, is a common finding that is inherited as an autosomal recessive trait [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/47,49\">",
"     47,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative frequency of these abnormalities was assessed in a study of 100 Japanese patients with a clinical diagnosis of Leigh syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/47\">",
"     47",
"    </a>",
"    ]. Enzymatic defects were found in 21 patients: 15 involved COX and four involved PDH. In addition, mtDNA mutations in the ATPase 6 coding region occurred in 18 patients; different point mutations were associated with different clinical courses.",
"   </p>",
"   <p>",
"    Despite the frequency of COX deficiency, no mutations of the nuclear encoded COX subunit genes have been found [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/50\">",
"     50",
"    </a>",
"    ]. However, mutations of SURF1, a gene located on chromosome 9q34, have been identified in many COX-deficient patients with Leigh syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. In one series, loss of function SURF-1 mutations were found in 18 of 24 (75 percent) patients with COX deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another nuclear gene that causes COX deficiency was identified through genetic linkage analysis of a consanguineous African family with an isolated COX defect [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/54\">",
"     54",
"    </a>",
"    ]. The gene is located on chromosome 17p13.1-q11.1, a region that encompasses two genes that encode proteins involved in COX assembly: SCO1 and COX10. The COX10 gene encodes heme A:farnesyltransferase, which catalyzes the first step in the conversion of protoheme to the heme A prosthetic groups. SCO1 is thought to be involved in mitochondrial copper transport to COX [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Leber hereditary optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leber hereditary optic neuropathy (LHON) is a maternally inherited bilateral subacute optic neuropathy caused by mutations in the mitochondrial genome. It is the first human disease to be associated with a mitochondrial DNA point mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three LHON mtDNA mutations at nucleotide positions 3460, 11778, and 14484 are specific for LHON. These mutations account for more than 90 percent of worldwide cases and are designated as primary [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/57\">",
"     57",
"    </a>",
"    ]. They are missense mutations in the subunit genes for the subunits of the electron transport chain complexes I, III, and IV. The three primary LHON mutations appear to cause profound impairment of complex I-dependent ATP synthesis, suggesting that they result in a common disease-causing mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the pathogenesis remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/56\">",
"     56",
"    </a>",
"    ]. At least 15 other secondary mutations have been identified, but their pathogenicity is unclear; they may serve as exacerbating genetic factors.",
"   </p>",
"   <p>",
"    LHON typically produces severe and permanent visual loss in men [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The initial symptoms include visual dysfunction with blurring of vision and loss of central vision, most often beginning in the late teens. However, variability in the age of onset, spectrum of clinical expression, and outcome exists.",
"   </p>",
"   <p>",
"    In one series of 72 patients with the 11778 mutation, 82 percent were males [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/60\">",
"     60",
"    </a>",
"    ]. The age at onset of visual loss ranged from 8 to 60 years, the time interval between affected eyes averaged 1.8 months, and progression to visual acuity of",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    or worse occurred in 98 percent of eyes over an average time of 3.7 months. Telangiectatic microangiopathy, disk pseudoedema, and vascular tortuosity, which are classic features of LHON, were seen in 58 percent of patients.",
"   </p>",
"   <p>",
"    However, not all patients have such rapid progression, as illustrated in a report of 53 patients, 15 of whom had favorable outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/61\">",
"     61",
"    </a>",
"    ]. In the latter group, seven had subclinical disease; two had slowly progressive LHON with a favorable visual outcome; and six had classic acute onset followed by spontaneous visual recovery. The visual outcome was better in families with the 3460 mutation than in those with the 11778 mutation.",
"   </p>",
"   <p>",
"    Numerous factors have been considered as potential explanations for the male predominance, variable penetrance, and variable phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/62\">",
"     62",
"    </a>",
"    ]. These factors include an additional X locus, impaired mitochondrial respiratory chain activity, mtDNA heteroplasmy, environmental factors and autoimmunity.",
"   </p>",
"   <p>",
"    Among environmental factors, smoking and alcohol intake may influence the expression of disease. Support for this hypothesis comes from an epidemiologic study of 125 LHON pedigrees with 196 affected and 206 unaffected carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/63\">",
"     63",
"    </a>",
"    ]. Both light and heavy cumulative smoking were independent risk factors for visual loss. In men who smoked, the lifetime clinical penetrance of visual loss was 93 percent. In addition, there was a trend towards increased visual failure with heavy alcohol intake.",
"   </p>",
"   <p>",
"    Features other than visual loss, including tremor and a multiple sclerosis-like illness, occasionally are present [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/64\">",
"     64",
"    </a>",
"    ]. Additional findings that can occur in children include an extrapyramidal syndrome, seizures, ataxia, spasticity, mental retardation, and peripheral neuropathy.",
"   </p>",
"   <p>",
"    Muscle biopsy shows abnormal mitochondria in the subsarcolemmal region by electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/59,65\">",
"     59,65",
"    </a>",
"    ]. In the CNS, demyelination of the optic tracts and cell loss and gliosis of the geniculate bodies occur, but the visual cortex is normal. Axonal depletion centrally in the optic nerve is present, as is loss of ganglion cells in the retina.",
"   </p>",
"   <p>",
"    The diagnosis typically is made by demonstration of the DNA point mutations. They can be detected using whole white blood cells. In addition, the defects in respiratory enzymes in the abnormal mitochondria can be demonstrated on muscle biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DNA REPAIR DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DNA repair disorders are characterized by susceptibility to chromosomal breakages, increased frequency of breaks, and interchanges occurring either spontaneously or following exposure to various DNA damaging agents. The underlying defect in these syndromes is the inability to repair a particular type of DNA damage [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/66\">",
"     66",
"    </a>",
"    ]. The inheritance of these disorders is autosomal recessive and they show an increased tendency to develop malignancies. Two of these disorders, xeroderma pigmentosum and the Cockayne syndrome, manifest a peripheral neuropathy (",
"    <a class=\"graphic graphic_table graphicRef52324 \" href=\"UTD.htm?39/16/40204\">",
"     table 1D",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Xeroderma pigmentosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xeroderma pigmentosum (XP) is a multigenic, multiallelic autosomal recessive disease that occurs in the United States at a frequency of approximately 1:250,000. Homozygotes have severe sun sensitivity that leads to degeneration of regions of the skin and eyes, leading to various forms of cutaneous malignancy. Mutations in eight genes have been identified. Seven of these genes (ie, XPA to XPG) are involved in nucleotide excision repair of carcinogen adducts after UV irradiation, while the other (ie, XPV) is involved in error-free replication of DNA damaged by UV irradiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link&amp;anchor=H12#H12\">",
"     \"Inherited susceptibility to melanoma\", section on 'Xeroderma pigmentosum genes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients with XP have neurologic abnormalities of varying severity caused by primary neuronal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/67\">",
"     67",
"    </a>",
"    ]. Neurologic features may be mild or severe and can include progressive cognitive impairment, ataxia, choreoathetosis, sensorineural hearing loss, spasticity, seizures, and peripheral neuropathy with diminished or absent deep tendon reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Acquired microcephaly also may be seen.",
"   </p>",
"   <p>",
"    The dermatologic manifestations of XP are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cockayne syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cockayne syndrome is a rare multisystem disorder with characteristic physical features and progressive dementia. The child typically is considered normal until two years of age. An unusual facies with large ears and sunken eyes occurs. The syndrome is characterized by severe physical and mental retardation, short stature, microcephaly, progressive neurologic dysfunction caused by demyelination, retinal degeneration with a pigmented retinopathy and optic atrophy, kyphoscoliosis, gait defects, and sun sensitivity but no increased frequency of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/70\">",
"     70",
"    </a>",
"    ]. In 13 cases confirmed with biochemical assays (unscheduled DNA synthesis and recovery of RNA synthesis in skin fibroblasts after exposure to UV irradiation), there was wide variation in the clinical manifestations ranging from prenatal features to normal psychomotor development [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that Cockayne syndrome should be considered in children with growth retardation, microcephaly and one of the characteristic features (eg, sunken eyes, limb ataxia, abnormal auditory evoked responses, or increased ventricular size and white matter changes on neuroimaging).",
"   </p>",
"   <p>",
"    Affected patients have white matter demyelination in the CNS, with atrophy of the cerebrum and cerebellum. Perivascular calcifications are seen in the basal ganglia and cerebellum. MRI scans show increased signal in the white matter with T2 images.",
"   </p>",
"   <p>",
"    Two complementation groups (CS-A and CS-B) have been identified, and 80 percent of patients have been assigned to the CS-B complementation group [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The CS-A gene encodes a WD repeat protein, which interacts with the CS-B protein to enhance the transcription factor II subunit of RNA polymerase II [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The CS-B protein is a helicase involved in the preferential repair of active genes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like XP, CS cells are hypersensitive to the lethal effects of UV light, but nucleotide excision repair of the bulk of genomic DNA is unaffected. CS cells are defective in a subpathway of nucleotide excision repair, known as transcription-coupled repair, whereby damage in the transcribed strand of active genes is rapidly and preferentially repaired [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Thus, in CS cells, damage in active genes is repaired at the same relatively slow rate as in the bulk DNA. It appears to be sufficient to prevent a predisposition to cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     HEREDITARY TYROSINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four autosomal recessive disorders result from deficiencies in specific enzymes in the tyrosine catabolic pathway: hereditary tyrosinemia (HT) types 1, 2, and 3, and alkaptonuria. These disorders summarized briefly below and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"     \"Disorders of tyrosine metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tyrosinemia type 1 (HT1) is the most severe disorder of tyrosine metabolism. It is characterized by severe progressive liver disease and renal tubular dysfunction. HT1 is caused by mutations in the fumarylacetoacetate hydrolase gene (FAH), which encodes the last enzyme in the tyrosine catabolic pathway.",
"     </li>",
"     <li>",
"      Tyrosinemia type 2 (Richner-Hanhart syndrome) is characterized by keratitis, palmoplantar hyperkeratosis, mental retardation, and elevated blood tyrosine levels [",
"      <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/79\">",
"       79",
"      </a>",
"      ]. The disease is caused by deficiency in hepatic tyrosine aminotransferase (TAT).",
"     </li>",
"     <li>",
"      Tyrosinemia type 3 is caused by deficiency of 4-hydroxyphenylpyruvate dioxygenase. It is an extremely rare disorder associated with hypertyrosinemia and elevated urinary excretion of 4-hydroxyphenyl derivatives. Affected patients have neurologic dysfunction, including ataxia, seizures, and mild psychomotor retardation, but no other systemic involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe neurologic manifestations can occur in children with HT1. These are due to the accumulation of succinylacetone, which is a potent inhibitor of ALA dehydratase (porphobilinogen synthase) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Thus, patients may have symptoms of ALA dehydratase porphyria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5656?source=see_link\">",
"     \"ALA dehydratase porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 48 children with tyrosinemia identified with neonatal screening, neurologic crises resembling the crises of the neuropathic porphyrias occurred in 20 (42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/37/602/abstract/82\">",
"     82",
"    </a>",
"    ]. These acute episodes of peripheral neuropathy were characterized by severe pain with extensor hypertonia (in 75 percent), vomiting or paralytic ileus (69 percent), muscle weakness (29 percent), and self-mutilation (8 percent). Eight children required mechanical ventilation because of paralysis. Between crises, most survivors regained normal function. Electrophysiologic studies in seven patients and neuromuscular biopsies in three patients showed axonal degeneration and secondary demyelination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"     \"Disorders of tyrosine metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21258289\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spinocerebellar ataxias are a heterogeneous group of inherited disorders with different neuropathological profiles reflecting the degree of cerebellar and brainstem dysfunction or degeneration. A peripheral neuropathy is described in some but not all. (",
"      <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"       table 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21258726\">",
"       'Spinocerebellar ataxias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infantile neuroaxonal dystrophy is an autosomal recessive disorder. It is considered one of several subtypes of neurodegeneration with brain iron accumulation (NBIA). Symptoms reflect involvement of the peripheral nerves, central nervous system, and autonomic nervous system (",
"      <a class=\"graphic graphic_table graphicRef72307 \" href=\"UTD.htm?31/28/32204\">",
"       table 1B",
"      </a>",
"      ). The usual onset ranges from ages 1 to 3 years. Manifestations include motor and cognitive regression, spasticity, muscle atrophy, hypotonia, cerebellar ataxia, dystonia, optic atrophy, and distal sensory loss. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Infantile neuroaxonal dystrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tangier disease is an autosomal codominant condition in which homozygotes have no serum high density lipoprotein (HDL) and heterozygotes have serum HDL concentrations of approximately one-half of those in normal individuals. Homozygotes develop cholesterol ester deposition in tonsils (orange tonsils), liver, spleen, gastrointestinal tract, lymph nodes, bone marrow, and Schwann cells. The main clinical manifestations are hepatosplenomegaly and premature coronary disease; a neuropathy occurs in at least 50 percent of patients and is the most debilitating feature of the disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tangier disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abetalipoproteinemia (Bassen-Kornzweig syndrome) is a rare autosomal recessive disorder that is characterized by defective assembly and secretion of apolipoprotein B (apo B) and apo B containing lipoproteins. A spectrum of clinical manifestations can be seen (",
"      <a class=\"graphic graphic_table graphicRef72307 \" href=\"UTD.htm?31/28/32204\">",
"       table 1B",
"      </a>",
"      ). All patients have neurologic manifestations such as retinitis pigmentosa, peripheral neuropathy, and ataxia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Abetalipoproteinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Refsum disease is a disorder of peroxisomal function. Classic Refsum disease is characterized by retinitis pigmentosa, peripheral polyneuropathy, cerebellar ataxia, and elevated cerebrospinal fluid protein concentration (",
"      <a class=\"graphic graphic_table graphicRef72307 \" href=\"UTD.htm?31/28/32204\">",
"       table 1B",
"      </a>",
"      ). Additional features may include sensorineural deafness, ichthyosis, anosmia, and cardiac conduction defects. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Refsum disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chediak-Higashi syndrome is an autosomal recessive disorder characterized by recurrent infections, partial albinism, hepatosplenomegaly, an increased risk of lymphoreticular malignancy, and multiple neurologic abnormalities (",
"      <a class=\"graphic graphic_table graphicRef72307 \" href=\"UTD.htm?31/28/32204\">",
"       table 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21258209\">",
"       'Chediak-Higashi syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lysosomal storage diseases are a group of approximately 36 heterogeneous disorders characterized by the accumulation of undigested macromolecules within the lysosomes. They result from a deficiency of a specific lysosomal enzyme or protein. Many are associated with a neurodegenerative phenotype, and a peripheral neuropathy occurs in Fabry disease, Krabbe disease, metachromatic leukodystrophy, and Niemann-Pick disease (",
"      <a class=\"graphic graphic_table graphicRef56567 \" href=\"UTD.htm?36/27/37308\">",
"       table 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lysosomal storage diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Defects in structure or function of mitochondria, mainly involving the oxidative phosphorylation, mitochondrial biogenesis and other metabolic pathways, are associated with a wide spectrum of clinical phenotypes. Peripheral neuropathy is a prominent feature in several (",
"      <a class=\"graphic graphic_table graphicRef52324 \" href=\"UTD.htm?39/16/40204\">",
"       table 1D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mitochondrial disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The DNA repair disorders are characterized by susceptibility to chromosomal breakages, increased frequency of breaks, and interchanges occurring either spontaneously or following exposure to various DNA damaging agents. The underlying defect in these syndromes is the inability to repair a particular type of DNA damage. The inheritance of these disorders is autosomal recessive and they show an increased tendency to develop malignancies. Two of these disorders, xeroderma pigmentosum and the Cockayne syndrome, manifest a peripheral neuropathy (",
"      <a class=\"graphic graphic_table graphicRef52324 \" href=\"UTD.htm?39/16/40204\">",
"       table 1D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'DNA repair disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Four autosomal recessive disorders result from deficiencies in specific enzymes in the tyrosine catabolic pathway; these are hereditary tyrosinemia (HT) types 1, 2, and 3, and alkaptonuria. Severe neurologic manifestations can occur in children with HT1, including acute episodes of peripheral neuropathy characterized by severe pain. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Hereditary tyrosinemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/1\">",
"      Flanigan K, Gardner K, Alderson K, et al. Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1. Am J Hum Genet 1996; 59:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/2\">",
"      Banfi S, Servadio A, Chung MY, et al. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 1994; 7:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/3\">",
"      Filla A, De Michele G, Santoro L, et al. Spinocerebellar ataxia type 2 in southern Italy: a clinical and molecular study of 30 families. J Neurol 1999; 246:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/4\">",
"      Sch&ouml;ls L, Amoiridis G, B&uuml;ttner T, et al. Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 1997; 42:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/5\">",
"      Sch&ouml;ls L, Kr&uuml;ger R, Amoiridis G, et al. Spinocerebellar ataxia type 6: genotype and phenotype in German kindreds. J Neurol Neurosurg Psychiatry 1998; 64:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/6\">",
"      Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006; 38:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/7\">",
"      Kurian MA, Morgan NV, MacPherson L, et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/8\">",
"      Gregory A, Westaway SK, Holm IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/9\">",
"      Aicardi J, Castelein P. Infantile neuroaxonal dystrophy. Brain 1979; 102:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/10\">",
"      Nardocci N, Zorzi G, Farina L, et al. Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria. Neurology 1999; 52:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/11\">",
"      Venkatesh S, Coulter DL, Kemper TD. Neuroaxonal dystrophy at birth with hypertonicity and basal ganglia mineralization. J Child Neurol 1994; 9:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/12\">",
"      Scheithauer BW, Forno LS, Dorfman LJ, Kane CA. Neuroaxonal dystrophy (Seitelberger's disease) with late onset, protracted course and myoclonic epilepsy. J Neurol Sci 1978; 36:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/13\">",
"      Farina L, Nardocci N, Bruzzone MG, et al. Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients. Neuroradiology 1999; 41:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/14\">",
"      McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/15\">",
"      Duncan C, Strub R, McGarry P, Duncan D. Peripheral nerve biopsy as an aid to diagnosis in infantile neuroaxonal dystrophy. Neurology 1970; 20:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/16\">",
"      Shimono M, Ohta M, Asada M, Kuroiwa Y. Infantile neuroaxonal dystrophy. Ultrastructural study of peripheral nerve. Acta Neuropathol 1976; 36:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/17\">",
"      Moretto G, Sparaco M, Monaco S, et al. Cytoskeletal changes and ubiquitin expression in dystrophic axons of Seitelberger's disease. Clin Neuropathol 1993; 12:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/18\">",
"      Ferreira RC, Mierau GW, Bateman JB. Conjunctival biopsy in infantile neuroaxonal dystrophy. Am J Ophthalmol 1997; 123:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/19\">",
"      Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/20\">",
"      Serfaty-Lacrosniere C, Civeira F, Lanzberg A, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/21\">",
"      Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/22\">",
"      Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/23\">",
"      Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/24\">",
"      Bodzioch M, Ors&oacute; E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/25\">",
"      Emmerich J, Verg&egrave;s B, Tauveron I, et al. Familial HDL deficiency due to marked hypercatabolism of normal apoA-I. Arterioscler Thromb 1993; 13:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/26\">",
"      Marcil M, Yu L, Krimbou L, et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler Thromb Vasc Biol 1999; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     Assman, G, von Eckardstein, A, Brewer, HB. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver, C, Beaudet, A, Sly, WS, Valle, D (Eds). The metabolic basis of inherited disease, 7th edition. McGraw-Hill, New York, 1995. p.2053.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/28\">",
"      Pietrini V, Rizzuto N, Vergani C, et al. Neuropathy in Tangier disease: A clinicopathologic study and a review of the literature. Acta Neurol Scand 1985; 72:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/29\">",
"      Gibbels E, Schaefer HE, Runne U, et al. Severe polyneuropathy in Tangier disease mimicking syringomyelia or leprosy. Clinical, biochemical, electrophysiological, and morphological evaluation, including electron microscopy of nerve, muscle, and skin biopsies. J Neurol 1985; 232:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/30\">",
"      Antoine JC, Tommasi M, Boucheron S, et al. Pathology of roots, spinal cord and brainstem in syringomyelia-like syndrome of Tangier disease. J Neurol Sci 1991; 106:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/31\">",
"      Hobbs HH, Rader DJ. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest 1999; 104:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/32\">",
"      Misra VP, King RH, Harding AE, et al. Peripheral neuropathy in the Chediak-Higashi syndrome. Acta Neuropathol 1991; 81:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/33\">",
"      Silveira-Moriyama L, Moriyama TS, Gabbi TV, et al. Chediak-Higashi syndrome with parkinsonism. Mov Disord 2004; 19:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/34\">",
"      Hauser RA, Friedlander J, Baker MJ, et al. Adult Chediak-Higashi parkinsonian syndrome with dystonia. Mov Disord 2000; 15:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/35\">",
"      Sung JH, Meyers JP, Stadlan EM, et al. Neuropathological changes in Ch&eacute;diak-Higashi disease. J Neuropathol Exp Neurol 1969; 28:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/36\">",
"      Lockman LA, Kennedy WR, White JG. The Chediak-Higashi syndrome: electrophysiological and electron microscopic observations on the peripheral neuropathy. J Pediatr 1967; 70:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/37\">",
"      LEIGH D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 1951; 14:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/38\">",
"      Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008; 39:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/39\">",
"      Lee HF, Tsai CR, Chi CS, et al. Leigh syndrome: clinical and neuroimaging follow-up. Pediatr Neurol 2009; 40:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/40\">",
"      Jacobs JM, Harding BN, Lake BD, et al. Peripheral neuropathy in Leigh's disease. Brain 1990; 113 ( Pt 2):447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/41\">",
"      Goebel HH, Bardosi A, Friede RL, et al. Sural nerve biopsy studies in Leigh's subacute necrotizing encephalomyelopathy. Muscle Nerve 1986; 9:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/42\">",
"      Loeffen J, Smeitink J, Triepels R, et al. The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. Am J Hum Genet 1998; 63:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/43\">",
"      Triepels RH, Van Den Heuvel LP, Trijbels JM, Smeitink JA. Respiratory chain complex I deficiency. Am J Med Genet 2001; 106:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/44\">",
"      Procaccio V, Wallace DC. Late-onset Leigh syndrome in a patient with mitochondrial complex I NDUFS8 mutations. Neurology 2004; 62:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/45\">",
"      DiMauro S, De Vivo DC. Genetic heterogeneity in Leigh syndrome. Ann Neurol 1996; 40:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/46\">",
"      Miyabayashi S, Ito T, Narisawa K, et al. Biochemical study in 28 children with lactic acidosis, in relation to Leigh's encephalomyelopathy. Eur J Pediatr 1985; 143:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/47\">",
"      Makino M, Horai S, Goto Y, Nonaka I. Mitochondrial DNA mutations in Leigh syndrome and their phylogenetic implications. J Hum Genet 2000; 45:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/48\">",
"      Santorelli FM, Shanske S, Macaya A, et al. The mutation at nt 8993 of mitochondrial DNA is a common cause of Leigh's syndrome. Ann Neurol 1993; 34:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/49\">",
"      DiMauro S, Servidei S, Zeviani M, et al. Cytochrome c oxidase deficiency in Leigh syndrome. Ann Neurol 1987; 22:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/50\">",
"      Jaksch M, Hofmann S, Kleinle S, et al. A systematic mutation screen of 10 nuclear and 25 mitochondrial candidate genes in 21 patients with cytochrome c oxidase (COX) deficiency shows tRNA(Ser)(UCN) mutations in a subgroup with syndromal encephalopathy. J Med Genet 1998; 35:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/51\">",
"      Zhu Z, Yao J, Johns T, et al. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 1998; 20:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/52\">",
"      Tiranti V, Jaksch M, Hofmann S, et al. Loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome c oxidase deficiency. Ann Neurol 1999; 46:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/53\">",
"      Teraoka M, Yokoyama Y, Ninomiya S, et al. Two novel mutations of SURF1 in Leigh syndrome with cytochrome c oxidase deficiency. Hum Genet 1999; 105:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/54\">",
"      Valnot I, von Kleist-Retzow JC, Barrientos A, et al. A mutation in the human heme A:farnesyltransferase gene (COX10 ) causes cytochrome c oxidase deficiency. Hum Mol Genet 2000; 9:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/55\">",
"      Horvath R, Lochm&uuml;ller H, Stucka R, et al. Characterization of human SCO1 and COX17 genes in mitochondrial cytochrome-c-oxidase deficiency. Biochem Biophys Res Commun 2000; 276:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/56\">",
"      Hirano M, DiMauro S. Leber hereditary optic neuropathy: biochemical lights in a blurry scenario. Arch Neurol 2005; 62:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/57\">",
"      Brown MD, Sun F, Wallace DC. Clustering of Caucasian Leber hereditary optic neuropathy patients containing the 11778 or 14484 mutations on an mtDNA lineage. Am J Hum Genet 1997; 60:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/58\">",
"      Baracca A, Solaini G, Sgarbi G, et al. Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol 2005; 62:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/59\">",
"      Uemura A, Osame M, Nakagawa M, et al. Leber's hereditary optic neuropathy: mitochondrial and biochemical studies on muscle biopsies. Br J Ophthalmol 1987; 71:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/60\">",
"      Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol 1991; 111:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/61\">",
"      Nikoskelainen EK, Huoponen K, Juvonen V, et al. Ophthalmologic findings in Leber hereditary optic neuropathy, with special reference to mtDNA mutations. Ophthalmology 1996; 103:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/62\">",
"      Chalmers RM, Schapira AH. Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. Biochim Biophys Acta 1999; 1410:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/63\">",
"      Kirkman MA, Yu-Wai-Man P, Korsten A, et al. Gene-environment interactions in Leber hereditary optic neuropathy. Brain 2009; 132:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/64\">",
"      Charlmers RM, Harding AE. A case-control study of Leber's hereditary optic neuropathy. Brain 1996; 119 ( Pt 5):1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/65\">",
"      Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/66\">",
"      Kraemer KH, Patronas NJ, Schiffmann R, et al. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience 2007; 145:1388.",
"     </a>",
"    </li>",
"    <li>",
"     Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1397/ (Accessed on December 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/68\">",
"      Kanda T, Oda M, Yonezawa M, et al. Peripheral neuropathy in xeroderma pigmentosum. Brain 1990; 113 ( Pt 4):1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/69\">",
"      Anttinen A, Koulu L, Nikoskelainen E, et al. Neurological symptoms and natural course of xeroderma pigmentosum. Brain 2008; 131:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/70\">",
"      Nance MA, Berry SA. Cockayne syndrome: review of 140 cases. Am J Med Genet 1992; 42:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/71\">",
"      Pasquier L, Laugel V, Lazaro L, et al. Wide clinical variability among 13 new Cockayne syndrome cases confirmed by biochemical assays. Arch Dis Child 2006; 91:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/72\">",
"      Cleaver JE, Thompson LH, Richardson AS, States JC. A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum Mutat 1999; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/73\">",
"      Mallery DL, Tanganelli B, Colella S, et al. Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome. Am J Hum Genet 1998; 62:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/74\">",
"      Henning KA, Li L, Iyer N, et al. The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 1995; 82:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/75\">",
"      Selby CP, Sancar A. Cockayne syndrome group B protein enhances elongation by RNA polymerase II. Proc Natl Acad Sci U S A 1997; 94:11205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/76\">",
"      Troelstra C, van Gool A, de Wit J, et al. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 1992; 71:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/77\">",
"      van der Horst GT, van Steeg H, Berg RJ, et al. Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell 1997; 89:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/78\">",
"      van Hoffen A, Natarajan AT, Mayne LV, et al. Deficient repair of the transcribed strand of active genes in Cockayne's syndrome cells. Nucleic Acids Res 1993; 21:5890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/79\">",
"      Goldsmith LA, Kang E, Bienfang DC, et al. Tyrosinemia with plantar and palmar keratosis and keratitis. J Pediatr 1973; 83:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/80\">",
"      Sassa S, Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 1983; 71:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/81\">",
"      Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A 1977; 74:4641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/37/602/abstract/82\">",
"      Mitchell G, Larochelle J, Lambert M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med 1990; 322:432.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6226 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_602=[""].join("\n");
var outline_f0_37_602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21258289\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21258726\">",
"      SPINOCEREBELLAR ATAXIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFANTILE NEUROAXONAL DYSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TANGIER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ABETALIPOPROTEINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REFSUM DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21258209\">",
"      CHEDIAK-HIGASHI SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LYSOSOMAL STORAGE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Niemann-Pick disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MITOCHONDRIAL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Leigh syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Leber hereditary optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DNA REPAIR DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Xeroderma pigmentosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cockayne syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      HEREDITARY TYROSINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21258289\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6226\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6226|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/59/11198\" title=\"table 1A\">",
"      Characteristics of SCA types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/28/32204\" title=\"table 1B\">",
"      Syndromic hereditary neurop I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/27/37308\" title=\"table 1C\">",
"      Lysosomal storage disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/16/40204\" title=\"table 1D\">",
"      Syndromic hereditary neurop II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5656?source=related_link\">",
"      ALA dehydratase porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=related_link\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33833?source=related_link\">",
"      Neuroacanthocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=related_link\">",
"      Neurologic manifestations of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20489?source=related_link\">",
"      Overview of Niemann-Pick disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_37_603="Criteria for gestational HTN";
var content_f0_37_603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for gestational hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Systolic blood pressure &ge;140 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diastolic blood pressure &ge; 90 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         AND",
"        </strong>",
"        no proteinuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developing",
"        <strong>",
"         AFTER",
"        </strong>",
"        the 20th week of gestation in women known to be normotensive before pregnancy. Blood pressure should be elevated on at least two occasions at least six hours apart.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_603=[""].join("\n");
var outline_f0_37_603=null;
var title_f0_37_604="Natural history of chronic AR";
var content_f0_37_604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Natural history of chronic aortic regurgitation mostly based upon data from nine series with a total of 593 patients followed for a mean of 6.6 years",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Asymptomatic patients with normal left ventricular (LV) systolic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression to symptoms and/or LV dysfunction",
"       </td>",
"       <td>",
"        Less than 6 percent/year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Progression to symptoms, LV dysfunction, or death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\" rowspan=\"1\">",
"        According to LV end-systolic dimension*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &gt;50 mm",
"       </td>",
"       <td class=\"sublist_other\">",
"        19 percent/year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        40 to 50 mm",
"       </td>",
"       <td class=\"sublist_other\">",
"        6 percent/year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &lt;40 mm",
"       </td>",
"       <td class=\"sublist_other\">",
"        0 percent/year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression to asymptomatic LV dysfunction",
"       </td>",
"       <td colspan=\"1\">",
"        Less than 3.5 percent/year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sudden death",
"       </td>",
"       <td colspan=\"1\">",
"        Less than 0.2 percent/year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Asymptomatic patients with LV systolic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression to cardiac symptoms",
"       </td>",
"       <td colspan=\"1\">",
"        More than 25 percent/year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\" rowspan=\"1\">",
"        Symptomatic patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mortality rate",
"       </td>",
"       <td colspan=\"1\">",
"        More than 10 percent/year",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow, RO, Lakatos, E, Maron, BJ, et al. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991; 84:1625.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_604=[""].join("\n");
var outline_f0_37_604=null;
var title_f0_37_605="Heart rate and VO2";
var content_f0_37_605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relation between heart rate and VO2 during exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between attained heart rate and oxygen uptake during exercise. One metabolic equivalent (MET) is defined as 3.5 mL O2 uptake/kg per min. Mean values of approximately 10 METs (VO2 35 mL/kg per min) can be achieved by nonathletic, healthy, middle-aged men; this should occur at a heart rate of approximately 175 beats/min.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_605=[""].join("\n");
var outline_f0_37_605=null;
var title_f0_37_606="Contents: Calculators";
var content_f0_37_606=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Calculators",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     <strong>",
"      Calculators",
"     </strong>",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Calculators",
"          <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?3/51/3902\">",
"         Cardiology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/61/28637\">",
"         Critical care calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/33/33309\">",
"         Emergency med calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?34/6/34925\">",
"         Endocrinology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/2/10286\">",
"         Gastroenterology and Hepatology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?38/34/39469\">",
"         General surgery calculators",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?40/23/41341\">",
"         Hematology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?25/50/26414\">",
"         Hospital medicine calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/59/33725\">",
"         ID calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?2/30/2542\">",
"         Nephrology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/63/28669\">",
"         Neurology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/44/27341\">",
"         Obstetrics calculators",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?27/29/28125\">",
"         Oncology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?20/55/21374\">",
"         Pediatrics calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/4/37965\">",
"         Primary care calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?39/44/40653\">",
"         Pulmonology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/5/30813\">",
"         Rheumatology calculators",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"       </tds>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-BE64F30A2A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f0_37_606=[""].join("\n");
var outline_f0_37_606=null;
var title_f0_37_607="Abciximab in stenting";
var content_f0_37_607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abciximab improves the outcome with stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 484px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the EPISTENT trial of 2399 patients undergoing emergent or elective angioplasty. Top panel: The 30-day incidence of the primary endpoint (death, MI, or need for urgent revascularization) was significantly lower among patients receiving a stent with abciximab compared to those undergoing angioplasty with abciximab therapy or stenting alone (5.3, 6.9, and 10.8 percent, respectively). Bottom panel: The benefit from abciximab primarily reflected a reduced incidence of death and of large non-Q wave MI (shown in blue).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The EPISTENT Investigators. Lancet 1998; 352:87.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_37_607=[""].join("\n");
var outline_f0_37_607=null;
